



(51) International Patent Classification:

A61K 51/04 (2006.01) A61K 49/08 (2006.01)
A61K 49/00 (2006.01)

(21) International Application Number:

PCT/US2017/050245

(22) International Filing Date:

06 September 2017 (06.09.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/384,478 07 September 2016 (07.09.2016) US

(71) Applicant: **THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS** [US/US]; 352 Henry Administration Building, 506 S. Wright St., Urbana, Illinois 61801 (US).


(72) Inventors: **MILLER, Lawrence**; 780 Southern Federal St., Apt. 401, Chicago, Illinois 60605 (US). **MOHAMADI, Ali**; 352 Henry Administration Building, 506 S. Wright St., Urbana, Illinois 61801 (US).

(74) Agent: **SEARS, John, S.**; THOMAS HORSTEMEYER LLP, 3200 Windy Hill Road SE, Suite 1600E, Atlanta, Georgia 30339 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METAL CHELATORS FOR IMAGING, THERAPEUTICS, AND BIOANALYSIS



(57) Abstract: A variety of compounds are provided capable of chelating a metal, in particular a lanthanide such as Eu(III) and Tb(III). Luminescent complexes of the compound and a metal ion are also provided, in particular luminescent metal complexes are provided containing a lanthanide such as Eu(III) or Tb(III) and a compound described herein. In some aspects, the luminescent complexes are capable of exhibiting bright emissions with high quantum yields. Methods of making the compound are provided. Methods of using the compounds and luminescent complexes are also provided, for example for imaging and therapeutic applications.

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*

METAL CHELATORS FOR IMAGING, THERAPEUTICS, AND BIOANALYSIS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to, and the benefit of, co-pending U.S. provisional application entitled "METAL CHELATORS FOR BIOANALYSIS AND IMAGING" having serial no. 62/384,478, filed September 7, 2016.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] This invention was made with government support under award R01GM081030 awarded by the National Institutes of Health. The government has certain rights in the invention.

TECHNICAL FIELD

[0003] The present disclosure generally relates to metal chelators, metal complexes formed therefrom, and methods of making and uses thereof; more specifically, exemplary aspects provide luminescent complexes formed from a metal and a chelator and methods of use for detecting the presence of an analyte in a sample.

BACKGROUND

[0004] A coordination complex is the product of a Lewis acid-base reaction in which neutral or anionic organic ligands form coordinate covalent bonds with a central metal atom or ion. Also known as metal chelators, coordination compounds are a critical component of several biomedical technologies. For example, compounds that contain coordination complexes of radioactive isotopes are used extensively in both cancer diagnostics and treatment as *in vivo* imaging contrast agents and for targeted radiation therapy, respectively.³⁰ Molecules that coordinate to Gd(III) are used as contrast agents for magnetic resonance imaging (MRI).³¹⁻³² A particular class of coordination compounds binds to lanthanide ions like Tb(III) or Eu(III) and contain organic chromophores that act to sensitize lanthanide-centered luminescence.³³ Lanthanide luminophores have photophysical properties such as ms-scale excited state lifetimes and multiple, narrow-line emission bands that make them uniquely suited for use in high throughput screening (HTS) in drug discovery,³³ immunoassays³⁴ and live-cell microscopy.³⁵

[0005] In order to function effectively in technological applications, metal chelators must meet a number of requirements. Firstly, they must be unimolecular constructs that can be

easily conjugated to antibodies, peptides or receptor-targeting ligands. So-called bifunctional chelators (BFCs) are widely used for targeting tumors in cancer imaging and therapeutics. Secondly, they must bind to a given metal ion with high thermodynamic stability and kinetic inertness. Kinetic inertness is the propensity to retain metal when diluted to extremely low concentrations (ca. nM) in the presence of large amounts of competing chelators and other metal ions. Such conditions are prevalent in blood, tissues, cell lysates or other environments where coordination compounds are used. While kinetic stability is paramount, the ability to form the metal complex rapidly is critical for radiometal binders because many isotopes have short half-lives. Moreover, it is desirable that metal complexation occur under mild physiological conditions so that antibody conjugates or other heat- or pH-sensitive preparations can be used effectively. Thirdly, the synthetic route to preparing metal chelators must be efficient, and ideally will be adaptable so that a single molecular scaffold can be used to prepare functional complexes of a wide variety of metals with different ionic radii and coordination numbers. For luminescent lanthanide complexes, the synthetic route must allow for efficient incorporation of sensitizing chromophores.

[0006] Hundreds of differently structured chelators have been prepared, and many are used in commercial bioassays or clinically. Among the reported structures, there are a handful of basic molecular architectures, or scaffolds, that have been widely used as a basis to create a diverse array of BFCs.³⁰ (See **FIG. 1**) These scaffolds vary in the degree to which they can be adapted for binding different metal ions, and they also vary in their ability to meet the stringent requirements for clinical or commercial application. For example, diethylamine triamine pentaacetic acid (DTPA) is a flexible linear, 8-coordinate chelator, and variants of DTPA have been used clinically for MRI (with Gd). While the formation kinetics of DTPA/metal complexes are favorable, their kinetic inertness can be extremely poor. By contrast, BFCs based on 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononane-triacetic acid (NOTA) exhibit excellent kinetic stability, and they have been used clinically for MRI and certain radiopharmaceutical applications. However, metallation of macrocycles like DOTA and NOTA analogues requires prolonged reaction at high temperatures and low pH, and this greatly limits their use with antibody conjugates or with radioisotopes with short half-lives. Other reported BFCs like Lumi4 (a luminescent Tb complex) and CHX-A"-DTPA exhibit both favorable metallation properties and good kinetic stability. However, their architecture limits their use to one or a few different metals.

[0007] Luminescent Tb(III) and Eu(III) complexes exhibit unique and useful photophysical properties including large Stokes shifts (>150 nm), long excited state lifetimes (μ s-ms) and multiple, narrow emission bands (<10 nm half-maximal) that span the visible spectrum.¹⁻²

Time-gated detection of long-lived lanthanide emission following pulsed excitation eliminates ns-scale fluorescence background and enables the development of highly sensitive diagnostic assays, high throughput screening methods or luminescence microscopy. In addition, the multiple emission bands afford exceptional multiplexing capabilities, especially when Tb(III) or Eu(III) complexes are used as Förster Resonance Energy Transfer (FRET) donors in combination with differently colored, fluorescent acceptors.³ To be used effectively in time-gated bio-analysis, lanthanide probes must meet several requirements including good brightness (the product of absorptivity and quantum yield of emission), strong and kinetically stable metal binding, bio-compatibility, and ease of synthesis and modification.⁴


[0008] There remains a need for a general chelator that can be easily modified structurally for use with a broad array of clinically and technologically relevant metal ions, including for Eu(III) and Tb(III), that exhibits requisite kinetic and thermodynamic metal binding stabilities, that complexes rapidly under benign physiological conditions and that can be easily appended with functional groups that enable easy conjugation to antibodies, peptides or other targeting molecules.

SUMMARY

[0009] Various solutions are provided that overcome one or more of the aforementioned deficiencies. In particular, a variety of compounds (chelators) are provided as well as luminescent complexes formed between the compounds and a metal ion. Methods of making the compounds and complexes are also provided, as are methods of using the compounds and luminescent complexes formed therefrom.

[0010] In some aspects, a class of lanthanide chelators are provided. In some aspects, the chelator is a compound according to Formula I or Formula II. In some aspects, the compound is based on cyclohexyl triethylenetetraamine hexaacetic acid (cyTTHA). In some aspects, functionalization of a central pendant carboxylic group with 7-aminoquinolinone (cs124) or 7-amino-4-trifluoromethyl-2-(1H)-quinolinone (cs124-CF3) sensitizer chromophores yielded Tb(III) and Eu(III) complexes with exceptional quantum yields in water (up to 54%), high absorptivity ($>15,000 \text{ M}^{-1} \text{ cm}^{-1}$ at 365 nm), fast metal complexation rates and kinetic stability comparable to "industry standard" cryptates and macrocycles. Moreover, the modular synthesis of cyTTHA described below provides a robust scaffold for preparing multifunctional metal complexes via selective N-alkylation of the chelator backbone.

[0011] In some aspects, a compound is provided having a formula according to Formula I or Formula II below.



[0012]

II

[0013] In some aspects, n_1 and n_4 are independently selected from integers of from 1 to 5, e.g. 2; and n_2 and n_3 are independently selected from integers of from 0 to 5, e.g. 0 or 1. In various aspects, R^1 , R^2 , R^3 and R^4 are independently selected from H, $-\text{CH}_2\text{COOH}$, $-\text{CH}_2\text{PO}(\text{OH})_2$, $-\text{CH}_2\text{CONH}_2$, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl. In some aspects, R^1 , R^2 , R^3 and R^4 are selected from the group consisting of $-\text{CH}_2\text{COOH}$, H, $-\text{CH}_2\text{PO}(\text{OH})_2$, $-\text{CH}_2\text{CONH}_2$, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl. In some aspects, R^2 , R^3 , and R^4 are each $-\text{CH}_2\text{COOH}$; while R^1 is selected from the group consisting of $-\text{CH}_2\text{COOH}$, H, $-\text{CH}_2\text{PO}(\text{OH})_2$, $-\text{CH}_2\text{CONH}_2$, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl.


[0014] In some aspects, R^5 , R^6 , R^7 and R^8 , are independently selected from H, substituted and unsubstituted alkyl, halogen, CN, CF_3 , acyl, $-\text{SO}_2\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{R}^{10}$, $-\text{OR}^9$, $-\text{SO}_2\text{R}^9$, $-\text{COOR}^9$, $-\text{SO}_2\text{OR}^9$, $-\text{OC}(\text{O})\text{R}^9$, $-\text{C}(\text{O})\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{C}(\text{O})\text{R}^{10}$, $-\text{NR}^9\text{SO}_2\text{R}^{10}$, $-\text{NO}_2$, $-\text{C}(\text{O})\text{NHNH}_2$, $-\text{NCO}$, $-\text{NCS}$, $-\text{N}_3$, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS

ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, 5-cholesten-3 β -ol, or R⁵, together with the atom to which it is attached and one or more of R⁶, R⁷, R⁸ forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl. In some aspects, R⁵, R⁷ and R⁸ are H, while R⁶ is selected from the group consisting of H, substituted and unsubstituted alkyl, halogen, CN, CF₃, acyl, -SO₂NR⁹R¹⁰, -NR⁹R¹⁰, -OR⁹, -SO₂R⁹, -COOR⁹, -SO₂OR⁹, -OC(O)R⁹, -C(O)NR⁹R¹⁰, -NR⁹C(O)R¹⁰, -NR⁹SO₂R¹⁰, -NO₂, -C(O)NHNH₂, -NCO, -NCS, -N₃, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, and 5-cholesten-3 β -ol.

[0015] In some aspects, R⁹ and R¹⁰ are independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl and substituted and unsubstituted heterocyclyl, or R⁹ and R¹⁰, together with the atoms to which they are attached, form a 5- to 7 membered substituted or unsubstituted heterocyclyl or heteroaryl.

[0016] In some aspects, L¹, L², L³, L⁴, L⁵, and L⁶, are independently none (i.e. absent) or selected from substituted and unsubstituted alkyl.

[0017] In some aspects, X¹ and X² are independently selected from H, halogen, -CHO, -COOH, -PO(OH)₂, -CONH₂, -C(O)NHNH₂, -NCO, -NCS, -N₃, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, 5-cholesten-3 β -ol, substituted and unsubstituted alkyl, substituted and unsubstituted alkynyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, fluorophores or chromophores that absorb light of a wavelength in the range of about 300 to about 420 nm, and a group of formula III:




III

wherein Y^1 , Y^2 , Y^3 , Y^4 are independently selected from H, substituted and unsubstituted alkyl, halogen, CN, CF_3 , acyl, $-SO_2NR^{11}R^{12}$, $-NR^{11}R^{12}$, $-OR^{11}$, $-SO_2R^{11}$, $-COOR^{11}$, $-SO_2OR^{11}$, $-OC(O)R^{11}$, $-C(O)NR^{11}R^{12}$, $-NR^{11}C(O)R^{12}$, $-NR^{11}SO_2R^{12}$, and $-NO_2$, or Y^1 together with the atom to which it is attached and one or more of Y^2 , Y^3 , Y^4 and forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl or substituted and unsubstituted heteroaryl. In some aspects, X^1 and X^2 are each independently selected from the group consisting of $-COOH$, $-PO(OH)_2$, and a sensitizer so long as at least one of X^1 and X^2 is a sensitizer. In some aspects, at least one of X^1 and X^2 is $-COOH$. In other aspects, both X^1 and X^2 are a sensitizer.


[0018] In some aspects, X^1 and X^2 are independently selected from halogen, $-CONH_2$, $-CHO$, $-C(O)NHNH_2$, $-COOH$, maleimidyl, thiazolidyl, haloacetyl, pyridyl disulfide, substituted and unsubstituted NHS ester, sulfonated NHS ester, succinimidyl, $-NCO$, $-NCS$, $-N_3$, substituted and unsubstituted alkynyl, tetrazolyl, substituted and unsubstituted cyclooctynyl, an amino acid moiety, and a phosphoramidite moiety. In some aspects, one or both of X^1 and X^2 are independently selected from tyramine, a tyramine derivative, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, and benzyl cytosine. In some aspects, one or both of X^1 and X^2 are independently selected from 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, and 5-cholesten-3 β -ol.

[0019] In Formula III above, R^{11} and R^{12} are independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl and substituted and unsubstituted heterocyclyl, or R^{11} and R^{12} , together with the atoms to which they are attached, are optionally joined to form a 5- to 7 membered heterocyclyl or heteroaryl;

[0020] Suitable sensitizers can include, for example,




where A and C are independently selected from N and CH; R is independently selected at each occurrence from H and $-OCH_3$; R' is selected from $-CH_3$, $-CF_3$, and $-CH_2COOH$; R'' is selected from H and $-CH_2COOH$; and R''' is selected from H and $-CH_3$. In some aspects, each occurrence of the sensitizer has a formula according to




where R', R'', and R''' are as defined above.

[0021] In some aspects, the compound is




where X is CH₃ or CF₃.

[0022] In some aspects, the compound is




where X is CH₃ or CF₃.


[0023] In some aspects, the compound is



[0024] In some aspects, the compound is




[0026] In some aspects, the compound is selected from the group consisting of




[0027] In the above formulas, L^x is independently selected at each occurrence from none, substituted and unsubstituted alkyl, substitute and unsubstituted heteroalkyl, substituted and unsubstituted heteroaryl, and substituted and unsubstituted heterocycloalkyl. In some

aspects, L^x has about 3 to 30 carbon atoms, about 3 to 20 carbon atoms, about 6 to 20 carbon atoms, or about 6 to 12 carbon atoms.

[0028] In the above formulas, R^x is independently selected at each occurrence from H, a halogen, substituted and unsubstituted alkyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted heteroaryl, substituted and unsubstituted heterocycloalkyl. In some aspects, R^x is independently selected at each occurrence from the following group



[0029] In some aspects, the compound is a compound according to Formula VIII:




[0030] In the above formula, A^1 and A^2 form together with the atoms to which they are attached a C_3 - C_8 -cycloalkyl group. In the above formula, A^3 and A^4 form together with the atoms to which they are attached a C_3 - C_8 -cycloalkyl group. In the above, Z is selected from the group consisting of $-CH_2-$, $-CH_2CH_2-$, $-CH_2CH_2OCH_2CH_2-$, and $-CH_2CH_2SCH_2CH_2-$.

[0031] In the above formula, n_5 , n_6 , n_7 , n_8 , n_9 and n_{10} are integers. In some aspects, n_5 , n_6 , n_7 , n_8 , n_9 and n_{10} are independently selected from integers from 0 to 5 or from 0 to 3 inclusive. In some aspects, n_{11} is selected from integers from 1 to 10, from 1 to 5, or from 5 to 10 inclusive. In some aspects, n_{12} and n_{13} are independently selected from integers of from 1 to 16, from 1 to 5, from 6 to 10, or from 11 to 16 inclusive. In some aspects, i is an

integer selected from integers of from 1 to n12 inclusive; and j is selected from integers of from 1 to n13 inclusive.

[0032] In the above formula, nQ^i and S^j are independently R, R^i or R^j , where R, R^i and R^j are independently selected from substituted and unsubstituted alkyl, halogen, CN, CF_3 , acyl, $-SO_2NR'R''$, $-NR'R''$, $-OR'$, $-SO_2R'$, $-COOR'$, $-SO_2OR'$, $-OC(O)R'$, $-C(O)NR'R'-NR''C(O)R''$, $-NR'SO_2R''$, $-NO_2$, $-C(O)NHNH_2$, $-NCO$, $-NCS$, $-N_3$, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, 5-cholesten-3 β -ol or R^i , together with the atom to which it is attached and one or more additional R^i , forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl or substituted and unsubstituted heteroaryl, or R^j , together with the atom to which it is attached and one or more additional R^j forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl. In the above, R' and R'' are independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, and substituted and unsubstituted heterocyclyl;


[0033] In the above, L^7 , L^8 , L^9 , L^{10} , L^{11} , and L^{12} are independently absent, H or selected from substituted and unsubstituted heteroalkyl, and substituted and unsubstituted alkyl. In the above, X^3 , X^4 , X^5 , X^6 , X^7 and X^8 are independently selected from H, halogen, $-CHO$, $-COOH$, $-PO(OH)_2$, $-CONH_2$, $-C(O)NHNH_2$, $-NCO$, $-NCS$, $-N_3$, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, 5-cholesten-3 β -ol, substituted and unsubstituted alkyl, substituted and unsubstituted alkynyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, fluorophores or chromophores that absorb light of a wavelength in the range of about 300 to about 420 nm, and compounds according to formula IX:



IX


In compound IX, Y⁹, Y¹⁰, Y¹¹, Y¹² are independently selected from H, substituted and unsubstituted alkyl, halogen, CN, CF₃, acyl, -SO₂NR^{13'}R^{13''}, -NR^{13'}R^{13''}, -OR^{13'}, -SO₂R^{13'}, -COOR^{13'}, -SO₂OR^{13'}, -OC(O)R^{13'}, -C(O)NR^{13'}R^{13''}, -NR^{13'}C(O)R^{13''}, -NR^{13'}SO₂R^{13''}, and -NO₂, or Y⁹ together with the atom to which it is attached and one or more of Y¹⁰, Y¹¹, Y¹² and forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl or substituted, and unsubstituted heteroaryl, where R^{13'} and R^{13''} are independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl and substituted, and unsubstituted heterocyclyl.

[0034] In some aspects, the compound is a compound according to Formula IX where at least one of X³, X⁴, X⁵, X⁶, X⁷ and X⁸ is the fluorophore or chromophore that absorbs light of a wavelength in the range of about 300 to about 420 nm, and the fluorophore or chromophore is selected from the group consisting of









wherein A and C are independently selected from N and CH; wherein R¹⁴ is independently selected at each occurrence from H and -OCH₃; wherein R^{14'} is selected from -CH₃, -CF₃, and -CH₂COOH; wherein R^{14''} is selected from H and -CH₂COOH; and wherein R^{14'''} is selected from H and -CH₃.

[0035] In some aspects, the compound is a compound according to Formula IX where the fluorophore or chromophore is a compound of formula:




wherein R^{14'}, R^{14''}, and R^{14'''} are as in Claim 7; and wherein R^{14''''} is selected from H and -CH₃.

[0036] In some aspects, the compound is selected from the group consisting of



where L_Y is independently at each occurrence selected from the group consisting of none, substituted and unsubstituted alkyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted heteroaryl, and substituted and unsubstituted heterocycloalkyl; and where R_Y is independently at each occurrence selected from the group consisting of hydrogen, a halogen, substituted and unsubstituted alkyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted heteroaryl, and substituted and unsubstituted heterocycloalkyl.

[0037] In some aspects, R_Y is selected from the group consisting of



[0038] Luminescent complexes are also provided. High brightness at relatively long excitation wavelengths is useful to minimize inner filter effects in bioassays, and it is critical for time-gated, luminescence microscopy because conventional optics do not effectively transmit below 350 nm.⁴⁻⁵ However, 1:1 ligand:metal complexes with brightness values exceeding 5000 M⁻¹ cm⁻¹ above 350 nm are rare.⁶⁻⁷ Disclosed herein are protein-targeted Tb(III) labels that can be used for intracellular, time-gated imaging.⁸⁻¹¹ These efforts have leveraged the exceptionally bright (QY, 54%) and kinetically stable Lumi4 Tb(III) complex which is compatible with the 365 nm LED excitation source of our microscope (ϵ_{365} , ca. 8500 M⁻¹ cm⁻¹).⁶


[0039] The luminescent complexes provided herein include a complex formed between a compound described herein and a metal atom or ion. In some aspects, the metal ion is a lanthanide. In some aspects, the metal ion is Eu(III) or Tb(III). The metal ion can include any stable or any radioactive isotope of a metal selected from the group consisting of Ga, In, Tl, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Sc, Y, Ti, Zr, Cr, Mn, Tc, Re, Fe, Ru, Co, Rh, Ir, Ni, Pd, Pt, Cu, Zn, Cd, Hg, Al, Ge, Sn, Pb, Sb, Bi, Te, Po, Mg, Ca, Sr, Ba, Ra, Ac, Th and U. The metal ion can include a metal ion selected from the group consisting of ⁶⁶Ga, ⁶⁷Ga, ⁶⁸, ¹¹¹In, ²⁰¹Tl, ¹⁴²Pr, ¹⁴⁹Pm, ¹⁵³Sm, ¹⁵³Gd, ¹⁵⁹Gd, ¹⁶⁶Ho, ¹⁷⁵Yb, ¹⁷⁷Lu, ⁴⁷Sc, ⁹⁰Y, ⁸⁹Zr, ⁵¹Cr, ^{99m}Tc, ¹⁸⁸Re, ¹⁸⁶Re, ⁵⁷Co, ^{101m}Rh, ⁶²Cu, ⁶⁴Cu, ⁶⁷Cu, ^{117m}Sn, ²⁰³Pb, ²¹²Pb, ²¹²Bi, ²¹³Bi, ²²³Ra, and ²²⁵Ac.

[0040] Various methods of making the compounds herein are also provided. In some aspects, the methods include a modular synthesis that follows a general reaction scheme of N-benzyl protection, N-alkylation with an alkyl halide, benzyl deprotection via hydrogenation, a second alkyl halide N-alkylation, and finally a sensitizer installation via a third alkylation.


[0041] In various aspects, methods of making the compounds are provided that include (i) alkylating a compound according to Formula I-C or Formula II-C with a compound according

to Formula IV to produce a first intermediate; (ii) alkylating the first intermediate with a compound according to Formula V to produce a second intermediate; and (iii) deprotecting the second intermediate to produce the compound according to Formula I or Formula II. In some aspects, the first alkylating step, the second alkylating step, or both alkylating steps are performed at about room temperature, e.g. about 65°C to 75°C.

[0042] The compound according to Formula I-C and Formula II-C are




[0043] The compounds according to Formula IV and Formula V are



[0044] In some aspects, the method further includes (a) alkylating a compound according to Formula I-B or Formula II-B with one or both of a compound according to Formula VI and a compound according to Formula VII followed by benzyl deprotection via hydrogenation to produce the compound according to Formula I-C or Formula II-C. The step of alkylating the compound according to Formula I-B or Formula II-B can be performed at a temperature of about 60°C, e.g. about 55°C to 65°C.


[0045] The compounds according to Formula I-B and Formula II-B are:




I-B

II-B

[0046] The compounds according to Formula VI and VII are



VI



VII

[0047] In the above formulas, Y^7 and Y^8 are each independently a halogen, preferably Br. In the above formulas, Y^5 and Y^6 are each independently a halogen such as Cl or Br, preferably Cl. In the above formula, n_1 , n_2 , n_3 , and n_4 are as defined above; and L^1 , L^2 , L^3 , L^4 , L^5 and L^6 , are as defined elsewhere herein.

[0048] In the above formulas, R^1 , R^2 , R^3 and R^4 are as defined elsewhere herein, except that the R^1 , R^2 , R^3 and R^4 can be protected with one or more protecting groups to protect from unwanted alkylation during the alkylation steps. For example, in some aspects the R^1 , R^2 , R^3 or R^4 include a carboxylic acid that is protected with a suitable carboxylic acid

protecting group, e.g. a methyl ester, a benzyl ester, or a tert-butyl ester. In some aspects, one or more (sometimes all) of R¹, R², R³, and R⁴ are each -CH₂COOtBu.

[0049] In the above formulas, R⁵, R⁶, R⁷ and R⁸ are as defined elsewhere herein, except that the R⁵, R⁶, R⁷ and R⁸ can be protected with one or more protecting groups to protect from unwanted alkylation during the alkylation steps. For example, in some aspects the R⁵, R⁶, R⁷ and R⁸ include a carboxylic acid that is protected with a suitable carboxylic acid protecting group, e.g. a methyl ester, a benzyl ester, or a tert-butyl ester.

[0050] In the above formulas, R⁹ and R¹⁰ are as defined elsewhere herein, except that R⁹ and R¹⁰ can be protected with one or more protecting groups to protect from unwanted alkylation during the alkylation steps. For example, in some aspects the R⁹ and R¹⁰ include a carboxylic acid that is protected with a suitable carboxylic acid protecting group, e.g. a methyl ester, a benzyl ester, or a tert-butyl ester.

[0051] In some aspects, a method is provided for detecting the presence of an analyte in a sample. The sample can be a living sample, for example the sample can be a human. The sample can include tissue such as muscles or organs. The method can include (a) contacting the sample with a composition comprising a luminescent complex described herein, (b) exciting the complex; and (c) detecting luminescence from the complex.

[0052] In some aspects, a method is provided for detecting the presence of an analyte in a sample, the method including: (a) contacting the sample and a composition comprising a luminescent complex according to any one of claims 12-14 and a luminescence modifying group; (b) exciting the complex; and (c) determining a luminescent property of the sample; wherein energy is transferred between the luminescent complex and the luminescence modifying group when the complex is excited; and wherein the presence of the analyte results in a change in the luminescent property. The complex and the luminescence modifying group can be part of the same molecule or they can be part of different molecules.

[0053] Other systems, methods, features, and advantages of compound, luminescent complexes, and methods of making and used thereof will be or become apparent to one with skill in the art upon examination of the following drawings and detailed description. It is intended that all such additional systems, methods, features, and advantages be included within this description, be within the scope of the present disclosure, and be protected by the accompanying claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Further aspects of the present disclosure will be readily appreciated upon review of the detailed description of its various embodiments, described below, when taken in conjunction with the accompanying drawings.

[0055] FIG. 1 is a figure of chelators used in various commercial or clinical applications.

[0056] FIG. 2 is a graph of the relative kinetic stability as measured by the luminescence signal intensity at ca. 545 nm (for Tb(III) complexes) or 620 nm (for Eu(III) complexes) for various dilute aqueous solutions (5 nM) of the indicated metal complexes in TBS buffer containing 1 mM EDTA.

[0057] FIG. 3 is a graph of the relative kinetic stability as measured by the luminescence signal intensity at ca. 545 nm (for Tb(III) complexes) or 620 nm (for Eu(III) complexes) for various dilute aqueous solutions (5 nM) of the indicated metal complexes in TBS buffer containing 1 mM EDTA.

DETAILED DESCRIPTION

[0058] In various aspects, modular synthetic strategies are provided allowing for the facile synthesis of a series of compounds (metal chelators) capable of forming luminescent complexes with a variety of metals. In particular, the compounds are suitable for chelating with lanthanide metals such as Eu(III) and Tb(III) to form luminescent complexes with exceptional brightness and stability needed for time-gated biosensing and microscopy applications.

[0059] Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. The skilled artisan will recognize many variants and adaptations of the embodiments described herein. These variants and adaptations are intended to be included in the teachings of this disclosure and to be encompassed by the claims herein.

[0060] All publications and patents cited in this specification are cited to disclose and describe the methods and/or materials in connection with which the publications are cited. All such publications and patents are herein incorporated by references as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. Such incorporation by reference is expressly limited to the methods and/or

materials described in the cited publications and patents and does not extend to any lexicographical definitions from the cited publications and patents. Any lexicographical definition in the publications and patents cited that is not also expressly repeated in the instant specification should not be treated as such and should not be read as defining any terms appearing in the accompanying claims. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided could be different from the actual publication dates that may need to be independently confirmed.

[0061] Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. Functions or constructions well-known in the art may not be described in detail for brevity and/or clarity. Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of organic chemistry, analytical chemistry, material science and engineering and the like, which are within the skill of the art. Such techniques are explained fully in the literature.

[0062] It should be noted that ratios, concentrations, amounts, and other numerical data can be expressed herein in a range format. It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. To illustrate, a numerical range of "about 0.1% to about 5%" should be interpreted to include not only the explicitly recited values of about 0.1% to about 5%, but also include individual values (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5%, 1.1%, 2.2%, 3.3%, and 4.4%) within the indicated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure, e.g. the phrase "x to y" includes the range from 'x' to 'y' as well as the range greater than 'x' and less than 'y'. The range can also be expressed as an upper limit, e.g. 'about x, y, z, or less' and should be interpreted to include the specific ranges of 'about x', 'about y', and 'about z' as well as the ranges of 'less than x', 'less than y', and 'less than z'. Likewise, the phrase 'about x, y, z, or greater' should be interpreted to include the specific ranges of 'about x', 'about y', and 'about z' as well as the ranges of 'greater than x', 'greater than y', and 'greater than z'. In some embodiments, the term "about" can include traditional rounding according to significant

figures of the numerical value. In addition, the phrase “about ‘x’ to ‘y’”, where ‘x’ and ‘y’ are numerical values, includes “about ‘x’ to about ‘y’”.

Definitions

[0063] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the specification and relevant art and should not be interpreted in an idealized or overly formal sense unless expressly defined herein.

[0064] The articles “a” and “an,” as used herein, mean one or more when applied to any feature in embodiments of the present invention described in the specification and claims. The use of “a” and “an” does not limit the meaning to a single feature unless such a limit is specifically stated. The article “the” preceding singular or plural nouns or noun phrases denotes a particular specified feature or particular specified features and may have a singular or plural connotation depending upon the context in which it is used.

[0065] “Alkenyl” as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons, unless otherwise specified, and containing at least one carbon-carbon double bond. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, 3-decenyl, and 3,7-dimethylocta-2,6-dienyl. In some aspects, alkenyl contains from 2 to 8 carbon atoms, from 2 to 6 carbon atoms, from 3 to 8 carbon atoms, or from 4 to 8 carbon atoms.

[0066] “Alkoxy” means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.

[0067] “Alkyl” means a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms unless otherwise specified. An alkyl chain may incorporate one or more O, S or NH groups, e.g. and ethylene glycol or poly(ethylene glycol) group. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. When an “alkyl” group is a linking group between two other moieties, then it may also be a straight or branched chain; examples include, but are not limited

to $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)-$, and $-\text{CH}_2\text{CH}(\text{CH}_2\text{CH}_3)\text{CH}_2-$. In some aspects, alkyl contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms.

[0068] “Alkynyl” means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl. In some aspects, alkynyl contains from 2 to 8 carbon atoms, from 2 to 6 carbon atoms, from 3 to 8 carbon atoms, or from 4 to 8 carbon atoms.

[0069] “Amino acid,” as used herein, refers to the twenty conventional amino acids. Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as α -, α -disubstituted amino acids, N-alkyl amino acids, and other unconventional amino acids may also be suitable components for the compound of the invention. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ -N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline).

[0070] The term “aryl,” as used herein, means a phenyl (*i.e.*, monocyclic aryl), or a bicyclic ring system containing at least one phenyl ring or an aromatic bicyclic ring containing only carbon atoms in the aromatic bicyclic ring system. The bicyclic aryl can be azulenyl, naphthyl, or a phenyl fused to a monocyclic cycloalkyl, a monocyclic cycloalkenyl, or a monocyclic heterocyclyl. The bicyclic aryl can be attached to the parent molecular moiety through any carbon atom contained within the phenyl portion of the bicyclic system, or any carbon atom with the naphthyl or azulenyl ring. The fused monocyclic cycloalkyl or monocyclic heterocyclyl portions of the bicyclic aryl are optionally substituted with one or two oxo and/or thia groups. Representative examples of the bicyclic aryls include, but are not limited to, azulenyl, naphthyl, dihydroinden-1-yl, dihydroinden-2-yl, dihydroinden-3-yl, dihydroinden-4-yl, 2,3-dihydroindol-4-yl, 2,3-dihydroindol-5-yl, 2,3-dihydroindol-6-yl, 2,3-dihydroindol-7-yl, inden-1-yl, inden-2-yl, inden-3-yl, inden-4-yl, dihydronaphthalen-2-yl, dihydronaphthalen-3-yl, dihydronaphthalen-4-yl, dihydronaphthalen-1-yl, 5,6,7,8-tetrahydronaphthalen-1-yl, 5,6,7,8-tetrahydronaphthalen-2-yl, 2,3-dihydrobenzofuran-4-yl, 2,3-dihydrobenzofuran-5-yl, 2,3-dihydrobenzofuran-6-yl, 2,3-dihydrobenzofuran-7-yl, benzo[d][1,3]dioxol-4-yl, benzo[d][1,3]dioxol-5-yl, 2H-chromen-2-on-5-yl, 2H-chromen-2-on-6-yl, 2H-chromen-2-on-7-yl, 2H-chromen-2-on-8-yl, isoindoline-1,3-dion-4-yl, isoindoline-1,3-dion-5-yl, inden-1-on-4-yl, inden-1-on-5-yl, inden-1-on-6-yl, inden-1-on-7-yl, 2,3-dihydrobenzo[b][1,4]dioxan-5-yl, 2,3-dihydrobenzo[b][1,4]dioxan-6-yl, 2H-benzo[b][1,4]oxazin3(4H)-on-5-yl, 2H-benzo[b][1,4]oxazin3(4H)-on-6-yl, 2H-benzo[b][1,4]oxazin3(4H)-on-7-yl, 2H-

benzo[b][1,4]oxazin-3(4H)-on-8-yl, benzo[d]oxazin-2(3H)-on-5-yl, benzo[d]oxazin-2(3H)-on-6-yl, benzo[d]oxazin-2(3H)-on-7-yl, benzo[d]oxazin-2(3H)-on-8-yl, quinazolin-4(3H)-on-5-yl, quinazolin-4(3H)-on-6-yl, quinazolin-4(3H)-on-7-yl, quinazolin-4(3H)-on-8-yl, quinoxalin-2(1H)-on-5-yl, quinoxalin-2(1H)-on-6-yl, quinoxalin-2(1H)-on-7-yl, quinoxalin-2(1H)-on-8-yl, benzo[d]thiazol-2(3H)-on-4-yl, benzo[d]thiazol-2(3H)-on-5-yl, benzo[d]thiazol-2(3H)-on-6-yl, and, benzo[d]thiazol-2(3H)-on-7-yl. In certain aspects, the bicyclic aryl is (i) naphthyl or (ii) a phenyl ring fused to either a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, or a 5 or 6 membered monocyclic heterocyclyl, wherein the fused cycloalkyl, cycloalkenyl, and heterocyclyl groups are optionally substituted with one or two groups which are independently oxo or thia. In certain aspects of the disclosure, the aryl group is phenyl or naphthyl. In certain other aspects, the aryl group is phenyl.

[0071] “Cyano” and “nitrile” mean a -CN group.

[0072] The term “cycloalkyl,” as used herein, means a monocyclic or a bicyclic alkyl ring system. Monocyclic ring systems are cyclic hydrocarbon groups containing from 3 to 8 carbon atoms, where such groups can be saturated or unsaturated, but not aromatic. In certain aspects, cycloalkyl groups are fully saturated. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Bicyclic cycloalkyl ring systems are bridged monocyclic rings or fused bicyclic rings. Bridged monocyclic rings contain a monocyclic cycloalkyl ring where two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms (*i.e.*, a bridging group of the form $-(CH_2)_w-$, where w is 1, 2, or 3). Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. Fused bicyclic cycloalkyl ring systems contain a monocyclic cycloalkyl ring fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. The bridged or fused bicyclic cycloalkyl is attached to the parent molecular moiety through any carbon atom contained within the monocyclic cycloalkyl ring. Cycloalkyl groups are optionally substituted with one or two groups which are independently oxo or thia. In certain aspects, the fused bicyclic cycloalkyl is a 5 or 6 membered monocyclic cycloalkyl ring fused to either a phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl, wherein the fused bicyclic cycloalkyl is optionally substituted by one or two groups which are independently oxo or thia. In certain aspects of the disclosure, the cycloalkyl is cyclopentyl, cyclohexyl, or cycloheptyl,

[0073] “Halo” or “halogen” mean -Cl, -Br, -I or -F. In certain aspects, “halo” or “halogen” refers to -Cl or -F.

[0074] “Haloalkyl” means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl. In certain aspects, each “haloalkyl” is a fluoroalkyl, for example, a polyfluoroalkyl such as a substantially perfluorinated alkyl.


[0075] “Heteroaryl,” means a monocyclic heteroaryl or a bicyclic ring system containing at least one heteroaromatic ring. The monocyclic heteroaryl can be a 5 or 6 membered ring. The 5 membered ring consists of two double bonds and one, two, three or four nitrogen atoms and optionally one oxygen or sulfur atom. The 6 membered ring consists of three double bonds and one, two, three or four nitrogen atoms. The 5 or 6 membered heteroaryl is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the heteroaryl. Representative examples of monocyclic heteroaryl include, but are not limited to, furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, and triazinyl. The bicyclic heteroaryl consists of a monocyclic heteroaryl fused to a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. The fused cycloalkyl or heterocyclyl portion of the bicyclic heteroaryl group is optionally substituted with one or two groups which are independently oxo or thia. When the bicyclic heteroaryl contains a fused cycloalkyl, cycloalkenyl, or heterocyclyl ring, then the bicyclic heteroaryl group is connected to the parent molecular moiety through any carbon or nitrogen atom contained within the monocyclic heteroaryl portion of the bicyclic ring system. When the bicyclic heteroaryl is a monocyclic heteroaryl fused to a phenyl ring, then the bicyclic heteroaryl group is connected to the parent molecular moiety through any carbon atom or nitrogen atom within the bicyclic ring system. Representative examples of bicyclic heteroaryl include, but are not limited to, benzimidazolyl, benzofuranyl, benzothienyl, benzoxadiazolyl, benzoxathiadiazolyl, benzothiazolyl, cinnolinyl, 5,6-dihydroquinolin-2-yl, 5,6-dihydroisoquinolin-1-yl, furopyridinyl, indazolyl, indolyl, isoquinolinyl, naphthyridinyl, quinolinyl, purinyl, 5,6,7,8-tetrahydroquinolin-2-yl, 5,6,7,8-tetrahydroquinolin-3-yl, 5,6,7,8-tetrahydroquinolin-4-yl, 5,6,7,8-tetrahydroisoquinolin-1-yl, thienopyridinyl, 4,5,6,7-tetrahydrobenzo[c][1,2,5]oxadiazolyl, and 6,7-dihydrobenzo[c][1,2,5]oxadiazol-4(5H)-onyl. In certain aspects, the fused bicyclic heteroaryl is a 5 or 6 membered monocyclic heteroaryl ring fused to either a phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6

membered monocyclic heteroaryl, wherein the fused cycloalkyl, cycloalkenyl, and heterocyclyl groups are optionally substituted with one or two groups which are independently oxo or thia. In certain aspects of the disclosure, the heteroaryl group is furyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, thiazolyl, thienyl, triazolyl, benzimidazolyl, benzofuranyl, indazolyl, indolyl, or quinolinyl.

[0076] The term “heterocyclyl” is used herein to refer both to a monocyclic heterocycle and a bicyclic heterocycle. The term “monocyclic heterocycle” is used herein to refer to a 3, 4, 5, 6 or 7 membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S where the ring is saturated or unsaturated, but not aromatic. The 3 or 4 membered ring can contain 1 heteroatom selected from the group consisting of O, N and S. The 5 membered ring can contain zero or one double bond. The 5 membered ring can also contain one, two or three heteroatoms selected from the group consisting of O, N and S. The 6 or 7 membered ring can contain zero, one or two double bonds; and can contain one, two or three heteroatoms selected from the group consisting of O, N and S. The monocyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the monocyclic heterocycle. Representative examples of monocyclic heterocycle include, but are not limited to, azetidiny, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazoliny, imidazolidiny, isothiazoliny, isothiazolidiny, isoxazoliny, isoxazolidiny, morpholiny, oxadiazoliny, oxadiazolidiny, oxazoliny, oxazolidiny, piperaziny, piperidinyl, pyranyl, pyrazoliny, pyrazolidiny, pyrroliny, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazoliny, thiadiazolidiny, thiazoliny, thiazolidiny, thiomorpholiny, 1,1-dioxidothiomorpholiny (thiomorpholine sulfone), thiopyranyl, and trithianyl. The term “bicyclic heterocycle” is used herein to refer to a monocyclic heterocycle fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heteroaryl, or to another monocyclic heterocycle that may be the same or different. The bicyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the monocyclic heterocycle portion of the bicyclic ring system. Representative examples of bicyclic heterocycles include, but are not limited to, 2,3-dihydrobenzofuran-2-yl, 2,3-dihydrobenzofuran-3-yl, indolin-1-yl, indolin-2-yl, indolin-3-yl, 2,3-dihydrobenzothien-2-yl, decahydroquinoliny, decahydroisoquinoliny, octahydro-1H-indolyl, and octahydrobenzofuranyl. Heterocyclyl groups are optionally substituted with one or two groups which are independently oxo or thia. In certain aspects, the bicyclic heterocyclyl is a 5 or 6 membered monocyclic heterocyclyl ring fused to phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl, wherein

the bicyclic heterocyclyl is optionally substituted by one or two groups which are independently oxo or thia. In certain aspects of the disclosure, the heterocyclyl is pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl.


[0077] “NHS ester” means a succinimidy ester, i.e. an ester of formula:



[0078] “Peptide,” as used herein, refers generally to a single linear chain of amino acids. The terms “peptide” and “fragment” refer to a linear chain of amino acids. In certain aspects, the peptide comprises less than about 100 amino acids. In other aspects, the peptide comprises less than about 50 amino acids. The peptide may also comprise one or more chemical modifications known in the art and/or described herein. The peptide can be produced by naturally-occurring organisms and specifically non-recombinant cells, or by genetically-engineered or recombinant cells, and comprise molecules having the amino acid sequence of the native protein, or sequences that have deletions, additions, and/or substitutions of one or more amino acids of the native sequence.

[0079] “Phosphoramidite” means a group of formula $-OP(NRR)_2OR$ where R is H or substituted or unsubstituted alkyl. An exemplary phosphoramidite group is $-OP(N-iPr)_2OCH_2CH_2CN$.

[0080] “Sulfonated NHS ester” as used herein, refers to a NHS ester as defined above substituted with a $-SO_3^-$ group. A representative sulfonated NHS ester is a group of formula:



[0081] The term “substituted” as used herein, refers to all permissible substituents of the compounds described herein. In the broadest sense, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, but are not

limited to, halogens, hydroxyl groups, or any other organic groupings containing any number of carbon atoms, preferably 1-14 carbon atoms, and optionally include one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats. Representative substituents include alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxyl, alkoxy, substituted alkoxy, phenoxy, substituted phenoxy, aroxy, substituted aroxy, alkylthio, substituted alkylthio, phenylthio, substituted phenylthio, arylthio, substituted arylthio, cyano, isocyano, substituted isocyano, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, sulfonyl, substituted sulfonyl, sulfonic acid, phosphoryl, substituted phosphoryl, phosphonyl, substituted phosphonyl, polyaryl, substituted polyaryl, C₃-C₂₀ cyclic, substituted C₃-C₂₀ cyclic, heterocyclic, substituted heterocyclic, aminoacid, peptide, and polypeptide groups.

[0082] When substituted, heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. It is understood that "substitution" or "substituted" includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, *i.e.* a compound that does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.

[0083] In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described herein. The permissible substituents can be one or more and the same or different for appropriate organic compounds. The heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms.

[0084] In various aspects, the substituent is selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, and thioketone, each of which optionally is substituted with one or more suitable substituents. In some aspects, the substituent is selected from alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cycloalkyl, ester, ether, formyl, haloalkyl, heteroaryl, heterocyclyl, ketone, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, and thioketone,


wherein each of the alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, carboxy, cycloalkyl, ester, ether, formyl, haloalkyl, heteroaryl, heterocyclyl, ketone, phosphate, sulfide, sulfinyl, sulfonyl, sulfonic acid, sulfonamide, and thioketone can be further substituted with one or more suitable substituents.

[0085] Examples of substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxy, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, thioketone, ester, heterocyclyl, -CN, aryl, aryloxy, perhaloalkoxy, aralkoxy, heteroaryl, heteroaryloxy, heteroarylalkyl, heteroaralkoxy, azido, alkylthio, oxo, acylalkyl, carboxy esters, carboxamido, acyloxy, aminoalkyl, alkylaminoaryl, alkylaryl, alkylaminoalkyl, alkoxyaryl, arylamino, aralkylamino, alkylsulfonyl, carboxamidoalkylaryl, carboxamidoaryl, hydroxyalkyl, haloalkyl, alkylaminoalkylcarboxy, aminocarboxamidoalkyl, cyano, alkoxyalkyl, perhaloalkyl, arylalkyloxyalkyl, and the like. In some aspects, the substituent is selected from cyano, halogen, hydroxyl, and nitro.

Compounds and Luminescent Complexes Thereof

[0086] In some aspects, a class of lanthanide chelators are provided. In some aspects, the chelator is a compound according to Formula I or Formula II. In some aspects, the compound is based on cyclohexyl triethylenetetraamine hexaacetic acid (cyTTHA). In some aspects, functionalization of a central pendant carboxylic group with 7-aminoquinolinone (cs124) or 7-amino-4-trifluoromethyl-2-(1H)-quinolinone (cs124-CF3) sensitizer chromophores yielded Tb(III) and Eu(III) complexes with exceptional quantum yields in water (up to 54%), high absorptivity (>15,000 M⁻¹ cm⁻¹ at 365 nm), fast metal complexation rates and kinetic stability comparable to "industry standard" cryptates and macrocycles. Moreover, the modular synthesis of cyTTHA described below provides a robust scaffold for preparing multifunctional metal complexes via selective N-alkylation of the chelator backbone.

[0087] In some aspects, a compound is provided having a formula according to Formula I or Formula II below.



[0088] In the above, n_1 , n_2 , n_3 , and n_4 are integers that can be chosen independently. In some aspects, n_1 and n_4 are independently selected from integers of from 1 to 5 or from 1 to 3. In some aspects, n_1 and n_4 are independently 1, 2, or 3. In some aspects, n_2 and n_3 are independently selected from integers of from 0 to 5 or from 0 to 3. In some aspects, n_2 and n_3 are independently 0, 1, 2, or 3.

[0089] In various aspects, R^1 , R^2 , R^3 and R^4 are independently selected from H, $-\text{CH}_2\text{COOH}$, $-\text{CH}_2\text{PO}(\text{OH})_2$, $-\text{CH}_2\text{CONH}_2$, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl. In some aspects, R^1 , R^2 , R^3 and R^4 are selected from the group consisting of $-\text{CH}_2\text{COOH}$, H, $-\text{CH}_2\text{PO}(\text{OH})_2$, $-\text{CH}_2\text{CONH}_2$, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl. In some aspects, R^1 , R^2 , R^3 and R^4 can have about 1 to 20, about 3 to 20, about 3 to 15, about 3 to 12, or about 6 to 12 carbon atoms. In some aspects, R^2 , R^3 , and R^4 are each $-\text{CH}_2\text{COOH}$; while R^1 is selected from the group consisting of $-\text{CH}_2\text{COOH}$, H, $-\text{CH}_2\text{PO}(\text{OH})_2$, $-\text{CH}_2\text{CONH}_2$, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl.

[0090] In some aspects, R^5 , R^6 , R^7 and R^8 , are independently selected from H, substituted and unsubstituted alkyl, halogen, CN, CF_3 , acyl, $-\text{SO}_2\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{R}^{10}$, $-\text{OR}^9$, $-\text{SO}_2\text{R}^9$, -


COOR⁹, -SO₂OR⁹, -OC(O)R⁹, -C(O)NR⁹R¹⁰ -NR⁹C(O)R¹⁰, -NR⁹SO₂R¹⁰, -NO₂, -C(O)NHNH₂, -NCO, -NCS, -N₃, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, 5-cholesten-3β-ol, or R⁵, together with the atom to which it is attached and one or more of R⁶, R⁷, R⁸ forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl. In some aspects, R⁵, R⁷ and R⁸ are H, while R⁶ is selected from the group consisting of H, substituted and unsubstituted alkyl, halogen, CN, CF₃, acyl, -SO₂NR⁹R¹⁰, -NR⁹R¹⁰, -OR⁹, -SO₂R⁹, -COOR⁹, -SO₂OR⁹, -OC(O)R⁹, -C(O)NR⁹R¹⁰ -NR⁹C(O)R¹⁰, -NR⁹SO₂R¹⁰, -NO₂, -C(O)NHNH₂, -NCO, -NCS, -N₃, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, and 5-cholesten-3β-ol.

[0091] In some aspects, R⁵, R⁶, R⁷, and R⁸ are independently selected from halogen, -CONH₂, -CHO, -C(O)NHNH₂, -COOH, maleimidyl, thiazolidyl, haloacetyl, pyridyl disulfide, substituted and unsubstituted NHS ester, sulfonated NHS ester, succinimidyl, -NCO, -NCS, -N₃, substituted and unsubstituted alkynyl, tetrazolyl, substituted and unsubstituted cyclooctynyl, an amino acid moiety, and a phosphoramidite moiety. In some aspects, R⁵, R⁶, R⁷, and R⁸ are independently selected from tyramine, a tyramine derivative, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, and benzyl cytosine. In some aspects, R⁵, R⁶, R⁷, and R⁸ are independently selected from 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, and 5-cholesten-3β-ol.

[0092] In some aspects, R⁹ and R¹⁰ are independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl and substituted and unsubstituted heterocyclyl, or R⁹ and R¹⁰, together with the atoms to which they are attached, form a 5- to 7 membered substituted or unsubstituted heterocyclyl or heteroaryl.

[0093] In some aspects, L¹, L², L³, L⁴, L⁵, and L⁶, are independently none (i.e. absent) or selected from substituted and unsubstituted alkyl.

[0094] In some aspects, X^1 and X^2 are independently selected from H, halogen, -CHO, -COOH, -PO(OH)₂, -CONH₂, -C(O)NHNH₂, -NCO, -NCS, -N₃, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, 5-cholesten-3 β -ol, substituted and unsubstituted alkyl, substituted and unsubstituted alkynyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, fluorophores or chromophores that absorb light of a wavelength in the range of about 300 to about 420 nm, and a group of formula III:



III


wherein Y^1 , Y^2 , Y^3 , Y^4 are independently selected from H, substituted and unsubstituted alkyl, halogen, CN, CF₃, acyl, -SO₂NR¹¹R¹², -NR¹¹R¹², -OR¹¹, -SO₂R¹¹, -COOR¹¹, -SO₂OR¹¹, -OC(O)R¹¹, -C(O)NR¹¹R¹², -NR¹¹C(O)R¹², -NR¹¹SO₂R¹², and -NO₂, or Y^1 together with the atom to which it is attached and one or more of Y^2 , Y^3 , Y^4 and forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl or substituted and unsubstituted heteroaryl. In some aspects, X^1 and X^2 are each independently selected from the group consisting of -COOH, -PO(OH)₂, and a sensitizer so long as at least one of X^1 and X^2 is a sensitizer. In some aspects, at least one of X^1 and X^2 is -COOH. In other aspects, both X^1 and X^2 are a sensitizer.

[0095] In some aspects, X^1 and X^2 are independently selected from halogen, -CONH₂, -CHO, -C(O)NHNH₂, -COOH, maleimidyl, thiazolidyl, haloacetyl, pyridyl disulfide, substituted and unsubstituted NHS ester, sulfonated NHS ester, succinimidyl, -NCO, -NCS, -N₃, substituted and unsubstituted alkynyl, tetrazolyl, substituted and unsubstituted cyclooctynyl, an amino acid moiety, and a phosphoramidite moiety. In some aspects, one or both of X^1 and

X^2 are independently selected from tyramine, a tyramine derivative, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, and benzyl cytosine. In some aspects, one or both of X^1 and X^2 are independently selected from 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, and 5-cholesten-3 β -ol.


[0096] In Formula III above, R^{11} and R^{12} are independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl and substituted and unsubstituted heterocyclyl, or R^{11} and R^{12} , together with the atoms to which they are attached, are optionally joined to form a 5- to 7 membered heterocyclyl or heteroaryl;

[0097] Suitable sensitizers can include, for example,




where A and C are independently selected from N and CH; R is independently selected at each occurrence from H and $-OCH_3$; R' is selected from $-CH_3$, $-CF_3$, and $-CH_2COOH$; R'' is

selected from H and $-\text{CH}_2\text{COOH}$; and R''' is selected from H and $-\text{CH}_3$. In some aspects, each occurrence of the sensitizer has a formula according to



where R' , R'' , and R''' are as defined above.


[0098] In some aspects, at least one of R^1 , R^2 , R^3 , R^4 , X^1 and X^2 are other than $-\text{CH}_2\text{COOH}$ or $-\text{CH}_2\text{PO}(\text{OH})_2$. The compounds do not include the following compounds where R is CH_3 or CF_3 .



[0099] In some aspects, the compound is a compound according to Formula I wherein R^1 is $-\text{CH}_2\text{COOH}$; wherein R^6 is H. In some aspects, the compound is a compound according to Formula II where R^1 is $-\text{CH}_2\text{COOH}$. In some aspects, the compound is according to Formula I or Formula II where L^3 , L^4 , L^5 , and L^6 are absent and R^5 , R^6 , R^7 , and R^8 are H. In some


aspects, the compound is according to Formula I or Formula II where R¹, R², R³, and R⁴ are -CH₂COOH. In some aspects, the compound is according to Formula I or Formula II wherein one of X¹ and X² is -COOH and the other is a fluorophore or chromophore that absorbs light of a wavelength in the range of about 300 to about 420 nm. For example, the fluorophore or chromophore can be any sensitizer described herein.

[0100] In some aspects, the compound is




where X is CH₃ or CF₃.

[0101] In some aspects, the compound is




where X is CH₃ or CF₃.


[0102] In some aspects, the compound is




[0103] In some aspects, the compound is



[0104] In some aspects, the compound is



[0105] In some aspects, the compound is selected from the group consisting of




[0106] In the above formulas, L^x is independently selected at each occurrence from none, substituted and unsubstituted alkyl, substitute and unsubstituted heteroalkyl, substituted and unsubstituted heteroaryl, and substituted and unsubstituted heterocycloalkyl. In some

aspects, L^x has about 3 to 30 carbon atoms, about 3 to 20 carbon atoms, about 6 to 20 carbon atoms, or about 6 to 12 carbon atoms.


[0107] In the above formulas, R^x is independently selected at each occurrence from H, a halogen, substituted and unsubstituted alkyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted heteroaryl, substituted and unsubstituted heterocycloalkyl. In some aspects, R^x has about 3 to 30 carbon atoms, about 3 to 20 carbon atoms, about 6 to 20 carbon atoms, or about 6 to 12 carbon atoms.

[0108] In some aspects, R_x is independently selected at each occurrence from the following group




[0109] In some aspects, a structural feature of the compounds (chelators) is the presence of two diaminocycloalkyl moieties that are linked by a bridge of variable length (e.g., $(-CH_2)_n$). The four cycloalkyl nitrogens serve as donor atoms, and pendant arms with variable numbers of donor atoms can be attached to the nitrogens. Thus, analogs of the chelators can be easily prepared that complex metal ions with different coordination numbers (e.g., compounds **i**, **ii** and **v** described below). Due to the inherent variability of the backbone of the metal chelators, it may be possible to stably bind metal ions of various diameters by varying the pendant coordinating structures (compounds **iii**, **iv**, **vi**, **viii** described below). Functional groups for conjugation can be attached to one of the cycloalkyl rings, or to the ring-bridging moiety (compound **vii** described below).

[0110] Accordingly, in some aspects the compounds is a compound of formula **i**, **ii**, **iii**, **iv**, **v**, **vi**, **vii**, or **viii**.



wherein FG refers to a functional group. The functional group can be used in conjugating to biomolecules.

[0111] In some aspects, the compound is a compound according to Formula VIII:




[0112] In the above formula, A¹ and A² form together with the atoms to which they are attached a C₃-C₈-cycloalkyl group. In the above formula, A³ and A⁴ form together with the atoms to which they are attached a C₃-C₈-cycloalkyl group. In the above, Z is selected from the group consisting of of -CH₂-, -CH₂CH₂-, -CH₂CH₂OCH₂CH₂-, and -CH₂CH₂SCH₂CH₂-.

[0113] In the above formula, n₅, n₆, n₇, n₈, n₉ and n₁₀ are integers. In some aspects, n₅, n₆, n₇, n₈, n₉ and n₁₀ are independently selected from integers from 0 to 5 or from 0 to 3 inclusive. In some aspects, n₁₁ is selected from integers from 1 to 10, from 1 to 5, or from 5 to 10 inclusive. In some aspects, n₁₂ and n₁₃ are independently selected from integers of from 1 to 16, from 1 to 5, from 6 to 10, or from 11 to 16 inclusive. In some aspects, i is an integer selected from integers of from 1 to n₁₂ inclusive; and j is selected from integers of from 1 to n₁₃ inclusive.

[0114] In the above formula, nQⁱ and S^j are independently R, Rⁱ or R^j, where R, Rⁱ and R^j are independently selected from substituted and unsubstituted alkyl, halogen, CN, CF₃, acyl, -SO₂NR'R'', -NR'R'', -OR', -SO₂R', -COOR', -SO₂OR', -OC(O)R', -C(O)NR'R'-NR'C(O)R'', -NR'SO₂R'', -NO₂, -C(O)NHNH₂, -NCO, -NCS, -N₃, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-sn-glycero-3-phosphoethanolamine, 1,2-dialkyl-sn-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, 5-cholesten-3β-ol or Rⁱ, together with the atom to which it is attached and one or more additional Rⁱ, forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl or substituted and unsubstituted heteroaryl, or R^j, together with the atom to which it is attached and one or more additional R^j forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl. In the above, R' and R'' are independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, and substituted and unsubstituted heterocyclyl;


[0115] In the above, L^7 , L^8 , L^9 , L^{10} , L^{11} , and L^{12} are independently absent, H or selected from substituted and unsubstituted heteroalkyl, and substituted and unsubstituted alkyl. In the above, X^3 , X^4 , X^5 , X^6 , X^7 and X^8 are independently selected from H, halogen, -CHO, -COOH, -PO(OH)₂, -CONH₂, -C(O)NHNH₂, -NCO, -NCS, -N₃, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, 5-cholesten-3 β -ol, substituted and unsubstituted alkyl, substituted and unsubstituted alkynyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, fluorophores or chromophores that absorb light of a wavelength in the range of about 300 to about 420 nm, and compounds according to formula IX:



IX


In compound IX, Y^9 , Y^{10} , Y^{11} , Y^{12} are independently selected from H, substituted and unsubstituted alkyl, halogen, CN, CF₃, acyl, -SO₂NR^{13'}R^{13''}, -NR^{13'}R^{13''}, -OR^{13'}, -SO₂R^{13'}, -COOR^{13'}, -SO₂OR^{13'}, -OC(O)R^{13'}, -C(O)NR^{13'}R^{13''}, -NR^{13'}C(O)R^{13''}, -NR^{13'}SO₂R^{13''}, and -NO₂, or Y^9 together with the atom to which it is attached and one or more of Y^{10} , Y^{11} , Y^{12} and forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl or substituted, and unsubstituted heteroaryl, where R^{13'} and R^{13''} are independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl and substituted, and unsubstituted heterocyclyl.

[0116] In some aspects, the compound is a compound according to Formula IX where at least one of X^3 , X^4 , X^5 , X^6 , X^7 and X^8 is the fluorophore or chromophore that absorbs light of a wavelength in the range of about 300 to about 420 nm, and the fluorophore or chromophore is selected from the group consisting of




wherein A and C are independently selected from N and CH; wherein R^{14} is independently selected at each occurrence from H and $-OCH_3$; wherein $R^{14'}$ is selected from $-CH_3$, $-CF_3$, and $-CH_2COOH$; wherein $R^{14''}$ is selected from H and $-CH_2COOH$; and wherein $R^{14'''}$ is selected from H and $-CH_3$.

[0117] In some aspects, the compound is a compound according to Formula IX where the fluorophore or chromophore is a compound of formula:




wherein $R^{14'}$, $R^{14''}$, and $R^{14'''}$ are as in Claim 7; and wherein $R^{14''''}$ is selected from H and $-CH_3$.

[0118] In some aspects, the compound is a compound according to Formula IX where the compound is selected from the group consisting of



where L_Y is independently at each occurrence selected from the group consisting of none, substituted and unsubstituted alkyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted heteroaryl, and substituted and unsubstituted heterocycloalkyl; and where R_Y is independently at each occurrence selected from the group consisting of hydrogen, a halogen, substituted and unsubstituted alkyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted heteroaryl, and substituted and unsubstituted heterocycloalkyl.

[0119] In some aspects, R_Y is selected from the group consisting of







[0120] Luminescent complexes are also provided. High brightness at relatively long excitation wavelengths is useful to minimize inner filter effects in bioassays, and it is critical for time-gated, luminescence microscopy because conventional optics do not effectively transmit below 350 nm.⁴⁻⁵ However, 1:1 ligand:metal complexes with brightness values exceeding 5000 M⁻¹ cm⁻¹ above 350 nm are rare.⁶⁻⁷ Disclosed herein are protein-targeted Tb(III) labels that can be used for intracellular, time-gated imaging.⁸⁻¹¹ These efforts have leveraged the exceptionally bright (QY, 54%) and kinetically stable Lumi4 Tb(III) complex which is compatible with the 365 nm LED excitation source of our microscope (ϵ_{365} , ca. 8500 M⁻¹ cm⁻¹).⁶

[0121] The luminescent complexes provided herein include a complex formed between a compound described herein and a metal atom or ion. In some aspects, the metal ion is a lanthanide. In some aspects, the metal ion is Eu(III) or Tb(III). The metal ion can include any stable or any radioactive isotope of a metal selected from the group consisting of Ga, In, Tl, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Sc, Y, Ti, Zr, Cr, Mn, Tc, Re, Fe, Ru, Co, Rh, Ir, Ni, Pd, Pt, Cu, Zn, Cd, Hg, Al, Ge, Sn, Pb, Sb, Bi, Te, Po, Mg, Ca, Sr, Ba, Ra, Ac, Th and U. The metal ion can include a metal ion selected from the group consisting of ⁶⁶Ga, ⁶⁷Ga, ⁶⁸, ¹¹¹In, ²⁰¹Tl, ¹⁴²Pr, ¹⁴⁹Pm, ¹⁵³Sm, ¹⁵³Gd, ¹⁵⁹Gd, ¹⁶⁶Ho, ¹⁷⁵Yb, ¹⁷⁷Lu, ⁴⁷Sc, ⁹⁰Y, ⁸⁹Zr, ⁵¹Cr, ^{99m}Tc, ¹⁸⁸Re, ¹⁸⁶Re, ⁵⁷Co, ^{101m}Rh, ⁶²Cu, ⁶⁴Cu, ⁶⁷Cu, ^{117m}Sn, ²⁰³Pb, ²¹²Pb, ²¹²Bi, ²¹³Bi, ²²³Ra, and ²²⁵Ac.

[0122] Many of the compounds described herein will be recognized as exhibiting stereoisomerism, enantiomerism and/or diastereomerism, as the case may be. Unless a specific stereoisomer is indicated, the disclosure will be understood to refer to all possible stereoisomers, so whenever a structure is shown in the stereochemical ambiguous form such as the structure of Formula I, it will be understood that the disclosure includes all possible stereoisomers as if each stereoisomer were individually and explicitly disclosed. Compositions containing the compounds described herein, where applicable, may contain a

racemic mixture or any other mixture of the stereoisomers. For example, in some aspects compositions contain a single stereoisomer or contain a non-racemic mixture of two or more stereoisomers where at least one stereoisomer has a greater relative concentration than would otherwise be present in a racemic mixture of the stereoisomers. As a specific non-limiting example, compounds according to Formula I can exist in any one of the following stereoisomers. Each of the following stereoisomers should be considered a part of the disclosure, as well as mixtures of two or more of the stereoisomers. Such mixtures can be racemic or otherwise.




Methods of Making Compounds and Luminescent Complexes Thereof

[0123] Various methods of making the compounds herein are also provided. In some aspects, the methods include a modular synthesis that follows a general reaction scheme of N-benzyl protection, N-alkylation with an alkyl halide, benzyl deprotection via hydrogenation, a second alkyl halide N-alkylation, and finally a sensitizer installation via a third alkylation.


The methods can allow for the synthesis of a variety of compounds described herein with overall yields in excess of 25% and without the need for HPLC purification. Since sensitizer inclusions occurs at or near the last step, the methods can be applied to insert a variety of sensitizers, fluorophores, and chromophores.

[0124] In various aspects, methods of making the compounds are provided that include (i) alkylating a compound according to Formula I-C or Formula II-C with a compound according to Formula IV to produce a first intermediate; (ii) alkylating the first intermediate with a compound according to Formula V to produce a second intermediate; and (iii) deprotecting the second intermediate to produce the compound according to Formula I or Formula II. In some aspects, the first alkylating step, the second alkylating step, or both alkylating steps are performed at about room temperature, e.g. about 65°C to 75°C.

[0125] The compound according to Formula I-C and Formula II-C are




[0126] The compounds according to Formula IV and Formula V are



[0127] In some aspects, the method further includes (a) alkylating a compound according to Formula I-B or Formula II-B with one or both of a compound according to Formula VI and a

compound according to Formula VII followed by benzyl deprotection via hydrogenation to produce the compound according to Formula I-C or Formula II-C. The step of alkylating the compound according to Formula I-B or Formula II-B can be performed at a temperature of about 60°C, e.g. about 55°C to 65°C.


[0128] The compounds according to Formula I-B and Formula II-B are:



I-B

II-B

[0129] The compounds according to Formula VI and VII are



VI

VII

[0130] In the above formulas, Y⁷ and Y⁸ are each independently a halogen, preferably Br. In the above formulas, Y⁵ and Y⁶ are each independently a halogen such as Cl or Br,

preferably Cl. In the above formula, n_1 , n_2 , n_3 , and n_4 are as defined above; and L^1 , L^2 , L^3 , L^4 , L^5 and L^6 , are as defined above.

[0131] In the above formulas, R^1 , R^2 , R^3 and R^4 are as defined above, except that the R^1 , R^2 , R^3 and R^4 can be protected with one or more protecting groups to protect from unwanted alkylation during the alkylation steps. Such protection chemistry is generally known to those skilled in the art. For example, in some aspects the R^1 , R^2 , R^3 or R^4 include a carboxylic acid that is protected with a suitable carboxylic acid protecting group, e.g. a methyl ester, a benzyl ester, or a tert-butyl ester. In some aspects, one or more (sometime all) of R^1 , R^2 , R^3 , and R^4 are each $-\text{CH}_2\text{COOtBu}$.

[0132] In the above formulas, R^5 , R^6 , R^7 and R^8 are as defined above, except that the R^5 , R^6 , R^7 and R^8 can be protected with one or more protecting groups to protect from unwanted alkylation during the alkylation steps. Such protection chemistry is generally known to those skilled in the art. For example, in some aspects the R^5 , R^6 , R^7 and R^8 include a carboxylic acid that is protected with a suitable carboxylic acid protecting group, e.g. a methyl ester, a benzyl ester, or a tert-butyl ester.

[0133] In the above formulas, R^9 and R^{10} are as defined above, except that R^9 and R^{10} can be protected with one or more protecting groups to protect from unwanted alkylation during the alkylation steps. Such protection chemistry is generally known to those skilled in the art. For example, in some aspects the R^9 and R^{10} include a carboxylic acid that is protected with a suitable carboxylic acid protecting group, e.g. a methyl ester, a benzyl ester, or a tert-butyl ester.

[0134] In the above formulas, X^1 and X^2 are as defined above, except that X^1 and X^2 can be protected with one or more protecting groups to protect from unwanted alkylation during the alkylation steps. Such protection chemistry is generally known to those skilled in the art. For example, in some aspects the X^1 and X^2 include a carboxylic acid that is protected with a suitable carboxylic acid protecting group, e.g. a methyl ester, a benzyl ester, or a tert-butyl ester.

[0135] In the above aspects, one or more groups can be protected with a suitable protecting group to prevent unwanted alkylation or other reactions that may occur during alkylation. Such protecting groups are generally described elsewhere. In some aspects, a carboxylic acid is protected with a suitable carboxylic acid protecting group. Carboxylic acid protecting groups can include a variety of esters such as methyl esters, benzyl esters, esters of 2,6-disubstituted phenols (e.g. 2,6-dimethylphenol, 2,6-diisopropylphenol, 2,6-di-tert-butylphenol), and silyl esters. In some aspects, an alcohol can be protected with a suitable

alcohol protecting group such as acetyl, methoxy methyl, or tetrahydrofuran. In some aspects, an amine is protected by a suitable amine protecting group such as tert-Butyloxycarbonyl, carbamate, and tosyl groups. In some aspects, the methods further include one or more protecting and deprotecting steps.

Methods of Using Compounds and Luminescent Complexes Thereof

[0136] The compounds provided herein can be used in a variety of manners, including but not limited to as therapeutics, e.g. as cancer therapeutics for carrying various radioisotopes, or for a variety of imaging applications.

[0137] In some aspects, a method is provided for detecting the presence of an analyte in a sample. The sample can be a living sample, for example the sample can be a human. The sample can include tissue such as muscles or organs. The method can include (a) contacting the sample with a composition comprising a luminescent complex described herein, (b) exciting the complex; and (c) detecting luminescence from the complex.

[0138] In some aspects, a method is provided for detecting the presence of an analyte in a sample, the method including: (a) contacting the sample and a composition comprising a luminescent complex according to any one of claims 12-14 and a luminescence modifying group; (b) exciting the complex; and (c) determining a luminescent property of the sample; wherein energy is transferred between the luminescent complex and the luminescence modifying group when the complex is excited; and wherein the presence of the analyte results in a change in the luminescent property. The complex and the luminescence modifying group can be part of the same molecule or they can be part of different molecules.

[0139] In some aspects, the analyte binds to an antibody, wherein the antibody is covalently linked to a member selected from a luminescence modifying group and a luminescent complex described herein.

[0140] In some aspects, the excitation of the complex is performed by irradiating the complex with light, in particular with near-UV light. The term "near-UV" as used herein means ultraviolet radiation having wavelengths in the range from about 315 nm to about 410 nm. In some aspects, the step of detecting luminescence includes detecting luminescence in the visible spectrum. As used herein, the visible spectrum includes wavelengths in the range of about 400 nm to about 700 nm.

[0141] In some aspects, the methods include time-gated detecting to eliminate background fluorescence. In some aspects, the samples include blood cells, tissues, and living cells. The methods can be particularly well suited for high-throughput screening.

EXAMPLES


[0142] Now having described the embodiments of the present disclosure, in general, the following Examples describe some additional embodiments of the present disclosure. While embodiments of the present disclosure are described in connection with the following examples and the corresponding text and figures, there is no intent to limit embodiments of the present disclosure to this description. On the contrary, the intent is to cover all alternatives, modifications, and equivalents included within the spirit and scope of embodiments of the present disclosure.

[0143] A modular synthesis was designed that followed a general reaction scheme of N-benzyl protection, N-alkylation with an alkyl halide, benzyl deprotection via hydrogenation, a second alkyl halide N-alkylation, and finally a sensitizer installation via a third alkylation. See Schemes 2 and 3. As with previously reported attempts to heterogeneously alkylate TTHA, we observed that formation of piperazin-2-one byproducts substantially lowered reaction yields,²¹⁻²² particularly when preparing the acyclic TTHA analogs. We minimized piperazin-2-one formation by first alkylating with two relatively bulky alkyl bromide groups and then running the subsequent alkylation reaction at room temperature.^{13, 14} Following this route, we prepared sensitized cyTTHA analogs **1a-b** and **3a-d** in 6 steps with good overall yields (25% for **3a**) and without the need for HPLC purification. Since sensitizer inclusion occurred in the last step, we further tested the generality of our strategy by substitution of a quinoline chromophore instead of carbostyryl in the central carboxylic arm to yield compound **2**.

[0144]

Synthetic Methods

[0145] The syntheses of representative compounds is shown in Schemes 1-4 and synthetic procedures below.



tert-butyl 2,2'-(2-hydroxyethylazanediyl)diacetate (S1)

[0146] In a round bottom flask, sodium carbonate (5.32 g, 50.2 mmol) and dry DMF (50 mL) were mixed and 2-Ethanolamine (1.20 mL, 20.0 mmol) was added in one portion, and the flask was placed in an ice bath. To this suspension, tert-butylbromoacetate (6.64 mL, 45.0 mmol, 2.25 equiv) was added over 1h. The contents were stirred for 24 h at RT. The reaction mixture was dissolved in a 1:1 mixture of EtOAc and water. The product was extracted with EtOAc and washed with brine (100 mL). The EtOAc layer was separated, dried over MgSO₄ and concentrated to obtain colorless viscous oil. The crude mixture purified via flash column chromatography over silica gel to obtain the product as colorless, viscous oil. Yield 99%. ¹H NMR (500 MHz, CDCl₃): δ ppm 3.47 (t, J= 10.0 Hz, 2H), 3.36 (s, 4H), 2.95 (t, J= 10.0 Hz, 2H), 1.34 (s, 9H). ¹³C NMR (126 MHz, CDCl₃): δ ppm 170.76, 81.37, 56.92, 42.53, 28.44. ESIMS (m/z) 290 [M+H]⁺, 312 [M+Na]⁺, 288 [M-H]⁻

tert-butyl 2,2'-(2-bromoethylazanediyl)diacetate (S2).

[0147] Starting with compound S1 (5.78 g, 20.0 mmol) and triphenylphosphine (7.86 g, 30.0 mmol, 1.5 equiv) were dissolved in dry DCM (100 mL) with in an ice bath. N-Bromosuccinimide (4.27 g, 24.0 mmol, 1.2 equiv) was added in small portions over 40 minutes. The contents were allowed to warm to the RT and stirred for 3 h under N₂ atmosphere. The solvent was removed on a rotavap to obtain brown-red viscous oil that was washed with diethyl ether and was filtered through a small silica column to obtain colorless viscous oil. The crude mixture was purified using flash chromatography over silica gel to obtain product as colorless, viscous oil. Yield 98%. ¹H NMR (500 MHz, CDCl₃): δ ppm 3.48 (s, 4H), 3.43 (t, J= 10.0 Hz, 2H), 3.12 (t, J= 10.0 Hz, 2H), 1.46 (s, 9H). ¹³C NMR

(126 MHz, CDCl₃): δ ppm 170.55, 81.32, 56.49, 30.33, 28.17. ESIMS (m/z) 352 [M+H]⁺, 374 [M+Na]⁺, 350 [M-H]⁻

7-amino-4-methylquinolin-2(1H)-one (S3).

[0148] 1,3-Phenylenediamine (1.08 g, 10.0 mmol) and ethyl acetoacetate (1.26 mL, 10.0 mmol) were refluxed for 48 h. Crystallization using MeOH gave colorless needle crystals. Yield 75%. ¹H NMR (500 MHz, DMSO-*d*6): δ ppm 11.14 (s, 1H), 7.31 (d, *J*= 10.0 Hz, 1H), 6.44 (dd, *J*= 10.0, 5.0 Hz, 1H), 6.35 (d, *J*= 5.0 Hz, 1H), 5.93 (s, 1H), 5.72 (s, 2H), 2.26 (s, 3H). ¹³C NMR (126 MHz, DMSO-*d*6): δ ppm 162.84, 151.52, 148.37, 141.23, 126.01, 115.12, 110.87, 97.26, 18.91. ESIMS (m/z) 175 [M+H]⁺, 197 [M+Na]⁺, 173 [M-H]⁻

7-amino-4-(trifluoromethyl)quinolin-2(1H)-one (S4).

[0149] 1,3- phenylenediamine (1.08 g, 10.0 mmol) and ethyl 4,4,4-trifluoro-3-oxobutanoate (1.46 mL, 10.0 mmol, 1 equiv) were refluxed for 24 h in 20 mL DMF. The crude mixture was purified using flash chromatography over silica gel to obtain product as a yellow powder. Yield 95%. ¹H NMR (500 MHz, DMSO-*d*6): δ ppm 11.83 (s, 1H), 7.35 (d, *J*= 10.0 Hz, 1H), 6.57 (d, *J*= 10.0 Hz, 1H), 6.47 (s, 1H), 6.44 (s, 1H), 6.16 (s, 2H). ¹³C NMR (126 MHz, DMSO-*d*6): δ ppm 161.34, 152.56, 142.62, 137.09-137.34, 125.58, 124.45, 113.93, 112.27, 103.96, 97.18. ESIMS (m/z) 229 [M+H]⁺, 251 [M+Na]⁺, 227 [M-H]⁻

2-chloro-N-(4-methyl-2-oxo-1,2-dihydroquinolin-7-yl)acetamide (S5).

[0150] To compound S3 (348 mg, 2.0 mmol) in DMF (0.20 M) was added NEt₃ (418 uL, 6.0 mmol, 3.0 equiv) and the solution was cooled to 0 °C before chloroacetyl chloride (159 uL, 1.0 equiv) diluted in DMF was added drop wise to the reaction solution. After 6 h, the reaction mixture was diluted with EtOAc and washed with H₂O and brine to give a grey precipitate in the organic layer. After filtration, the solid was dried under high vacuum to give compound S5 as a white solid (76%). ¹H NMR (500 MHz, DMSO-*d*6): δ ppm 11.60 (s, 1H), 10.67 (s, 1H), 7.77 (s, 1H), 7.66 (d, *J*= 10.0 Hz, 1H), 7.35 (d, *J*= 10.0 Hz, 1H), 6.29 (s, 1H), 3.36 (s, 2H), 2.39 (s, 3H). ¹³C NMR (126 MHz, DMSO-*d*6): δ ppm 165.45, 162.42, 148.05, 140.62, 139.90, 125.92, 119.79, 116.40, 114.02, 105.24, 44.08, 18.86. ESIMS (m/z) 251 [M+H]⁺, 273 [M+Na]⁺, 249 [M-H]⁻

2-chloro-N-(2-oxo-4-(trifluoromethyl)-1,2-dihydroquinolin-7-yl)acetamide (S6).

[0151] To compound S4 (456 mg, 2.0 mmol) in DMF (0.20 M) was added NEt₃ (418 uL, 6.0 mmol, 3.0 equiv) and the solution was cooled to 0 °C before chloroacetyl chloride (159 uL, 2.0 mmol, 1.0 equiv) diluted in DMF was added drop wise to the reaction solution. After 6 h, water 100 mL, 50 mL EtOAc was added. The aqueous layer was extracted twice more with


EtOAc (100 mL). The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo to afford a yellow solid. The crude product was purified by silica gel column chromatography. Yield 76%. ¹H NMR (500 MHz, DMSO-*d*₆): δ ppm 12.29 (s, 1H), 10.80 (s, 1H), 7.95 (s, 1H), 7.66 (d, *J*= 10.0 Hz, 1H), 7.40 (d, *J*= 10.0 Hz, 1H), 6.82 (s, 1H), 3.32 (s, 2H). ¹³C NMR (126 MHz, DMSO-*d*₆): δ ppm 165.80, 160.80, 141.73, 141.26, 136.58, 125.54, 120.18, 115.24, 109.62, 105.68, 44.05. ESIMS (*m/z*) 305 [M+H]⁺, 327 [M+Na]⁺, 303 [M-H]⁻

7-amino-4-methyl-1-(prop-2-ynyl)quinolin-2(1H)-one (S7).

[0152] To compound S3 (2.0 mmol, 348 mg) in DMF (0.2 M) was added 1.0 equiv of 10 M NaOH and stirred at room temperature for 15 min. Propargyl bromide (178 μL, 2.0 mmol, 1.0 equiv) was added drop wise and stirred at 60°C. After 12 h, water 100 mL, 50 mL EtOAc was added. The aqueous layer was extracted twice more with EtOAc (100 mL). The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo to afford a yellow solid. The crude product was purified by silica gel column chromatography. Yield 80%. ¹H NMR (500 MHz, MeOD): δ ppm 7.42 (d, *J*= 10.0 Hz, 1H), 6.54-6.59 (m, 2H), 6.09 (s, 1H), 5.95 (s, 2H), 4.89 (s, 2H), 3.19 (s, 1H), 2.28 (s, 3H). ¹³C NMR (126 MHz, MeOD): δ ppm 161.05, 152.15, 148.06, 140.65, 127.14, 113.90, 111.51, 110.58, 97.58, 79.92, 74.48, 31.05, 18.96. ESIMS (*m/z*) 213 [M+H]⁺, 235 [M+Na]⁺, 211 [M-H]⁻

chloro-N-(4-methyl-2-oxo-1-(prop-2-ynyl)-1,2-dihydroquinolin-7-yl)acetamide (S8).

[0153] Prepared in similar way as compound S5, except compound S7 used in place of compound S3. Yield 81%. ¹H NMR (500 MHz, MeOD): δ ppm 11.20 (s, 1H), 8.06 (s, 1H), 7.75 (d, *J*= 10.0 Hz, 1H), 7.57-7.60 (m, 2H), 6.44 (s, 1H), 4.95 (s, 2H), 4.42 (s, 2H), 3.27-3.28 (m, 1H), 2.40 (s, 3H). ¹³C NMR (126 MHz, MeOD): δ ppm 166.14, 161.09, 148.23, 141.90, 139.57, 127.23, 118.97, 117.74, 114.57, 105.28, 79.60, 75.44, 44.52, 31.76, 19.32. ESIMS (*m/z*) 289 [M+H]⁺, 311 [M+Na]⁺, 287 [M-H]⁻



N,N'-(Benzyl)ethylenediamine (1)

[0154] To a solution of ethylenediamine (2.82 mL, 20.0 mmol) in dry methanol (100 mL) was added benzaldehyde (4.06 mL, 40.0 mmol, 2 equiv). The solution was refluxed for 10 h and then cooled via an ice bath. Addition of NaBH₄ (3.25 g, 86 mmol, 4.3 equiv) was performed slowly and in small portions to prevent boiling, and the reaction mixture was stirred for 4 h until completion. The solvent was evaporated in vacuo, and then saturated NaHCO₃ (50 mL), water (50 mL) and dichloromethane (200 mL) were added. The aqueous layer was extracted twice more with dichloromethane (100 mL). The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo to afford a waxy, yellow solid. Product was purified by silica column chromatography to afford 1 as yellow oil. Yield 62%. ¹H NMR (500 MHz, CDCl₃): δ ppm 7.36 (d, *J* = 5.0 Hz, 8H), 7.30 (m, 2H), 3.81 (s, 4H), 2.79 (s, 4H), 1.63 (s, 2H). ¹³C NMR (126 MHz, CDCl₃): δ ppm 140.68, 128.45, 128.20, 126.96, 54.02, 48.92, 241. ESIMS (*m/z*) 241 [M+H]⁺, 263 [M+Na]⁺, 239 [M-H]⁻

di-tert-butyl 6,9-dibenzyl-3,12-bis(2-tert-butoxy-2-oxoethyl)-3,6,9,12-tetraazatetradecane-1,14-dioate (2)

[0155] To a solution of compound 1 (2.40 g, 10.0 mmol) and compound S2 (7.39 g, 21.0 mmol, 2.1 equiv) in DMF was added sodium carbonate (3.17 g, 3.0 equiv). The solution was

heated for 24 hours at 60°C under N₂. Sodium carbonate was removed by filtration. The filtrate was washed with H₂O and aqueous phase extracted twice with EtOAc. The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo. Product was purified by silica column chromatography to afford **2** as yellow oil. Yield 89%. ¹H NMR (500 MHz, CDCl₃): δ ppm 7.24-7.26 (m, 10H), 3.55 (s, 4H), 3.37 (s, 8H), 2.75-2.77 (m, 4H), 2.55-2.57 (m, 8H), 1.41 (s, 36H). ¹³C NMR (126 MHz, CDCl₃): δ ppm 170.69, 139.64, 128.80, 128.09, 126.73, 80.71, 59.23, 56.14, 53.07, 52.13, 28.17. ESIMS (m/z) 783 [M+H]⁺, 805 [M+Na]⁺, 781 [M-H]⁻

di-tert-butyl 3,12-bis(2-tert-butoxy-2-oxoethyl)-3,6,9,12-tetraazatetradecane-1,14-dioate (3).

[0156] To a solution of compound **2** (1.62 g, 2.0 mmol) in methanol (7 mL) was added Pd/C (200 mg, 10 wt %). Hydrogen gas was bubbled through the solution for 3 min, and then the reaction mixture was stirred under hydrogen for 18 h. The Pd/C was filtered out over Celite, rinsing well with methanol, and the filtrate was evaporated to dryness in vacuo. The crude product was purified by silica gel column chromatography. Product fractions were combined and concentrated in vacuo to afford the product **3** as a waxy yellow solid. Yield 95%. ¹H NMR (500 MHz, MeOD): δ ppm 3.55 (s, 8H), 3.13-3.23 (m, 12H), 1.49 (s, 36H). ¹³C NMR (126 MHz, MeOD): δ ppm 172.01, 81.64, 56.48, 50.83, 46.11, 43.39. ESIMS (m/z) 603 [M+H]⁺, 625 [M+Na]⁺, 601 [M-H]⁻

di-tert-butyl 3,6,12-tris(2-tert-butoxy-2-oxoethyl)-3,6,9,12-tetraazatetradecane-1,14-dioate (4)

[0157] To a solution compound **3** (1.2 g, 2.0 mmol) and sodium carbonate (423 mg, 4.0 mmol, 2.0 equiv) in dry acetonitrile was added dropwise a solution of tertbutyl bromoacetate (295 uL, 2.0 mmol, 1.0 equiv). The reaction mixture was stirred for 18 h at room temperature. Sodium carbonate was filtered and the filtrate concentrated in vacuo to dryness. EtOAc and water were added and aqueous layer were extracted twice with EtOAc. The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo to afford a waxy, yellow solid. Product was purified by silica column chromatography to afford compound **4** as yellow oil. Yield 90%. ¹H NMR (500 MHz, CDCl₃): δ ppm 2.82-3.18 (m, 16H), 2.40-2.50 (m, 6H), 1.10-1.15 (m, 45H). ESIMS (m/z) 717 [M+H]⁺, 739 [M+Na]⁺, 715 [M-H]⁻


di-tert-butyl 3,6,12-tris(2-tert-butoxy-2-oxoethyl)-9-(2-(4-methyl-2-oxo-1,2-dihydroquinolin-7-ylamino)-2-oxoethyl)-3,6,9,12-tetraazatetradecane-1,14-dioate (5a)

[0158] To compound **4** (143 mg, 0.2 mmol) and compound S5 (55 mg, 0.22 mmol, 1.1 equiv) in 10 mL DMF was added sodium carbonate (42 mg, 0.4 mmol, 2.0 equiv), and the

reaction mixture was heated to 60 °C for 24 h under nitrogen. After cooling to room temperature, the reaction mixture was diluted with EtOAc, washed with H₂O and brine, aqueous layer were extracted twice with EtOAc. The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo to afford a waxy, yellow solid. Product was purified by silica column chromatography to afford **5a** as yellow oil. Yield 60%. ¹H NMR (500 MHz, CDCl₃): δ ppm 7.55-7.78 (m, 3H), 6.41 (s, 1H), 3.34-3.46 (m, 12H), 2.74-2.84 (m, 12H), 2.44 (s, 3H), 1.40-1.45 (m, 45H). ESIMS (m/z) 931 [M+H]⁺, 953 [M+Na]⁺, 929 [M-H]⁻

di-tert-butyl 3,6,12-tris(2-tert-butoxy-2-oxoethyl)-9-(2-oxo-2-(2-oxo-4-(trifluoromethyl)-1,2-dihydroquinolin-7-ylamino)ethyl)-3,6,9,12-tetraazatetradecane-1,14-dioate (5b)

[0159] Prepared in a similar way as compound 5a, except compound S6 was used instead of compound S5. Yield 55%. ¹H NMR (500 MHz, CDCl₃): δ ppm 7.63-8.19 (m, 3H), 6.90 (s, 1H), 3.34-3.47 (m, 12H), 2.74-2.88 (m, 12H), 1.40-1.45 (m, 45H). ESIMS (m/z) 985 [M+H]⁺, 1007 [M+Na]⁺, 983 [M-H]⁻



(1S,2S)-N1,N2-dibenzylcyclohexane-1,2-diamine (7)

[0160] To a solution of (1S,2S)-cyclohexane-1,2-diamine (1.14 g, 10.0 mmol) in dry methanol was added benzaldehyde (2.03 mL, 20.0 mmol, 2 equiv). The solution was refluxed for 4 h and then cooled via an ice bath. Addition of NaBH₄ (1.62 g, 43.0 mmol, 4.3 equiv) was performed slowly and in small portions to prevent boiling, and the reaction

mixture was stirred for 12 h until completion. The solvent was evaporated in vacuo, and then saturated NaHCO₃ (50 mL), water (50 mL) and dichloromethane (200 mL) were added. The aqueous layer was extracted twice more with dichloromethane (100 mL). The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo to afford a waxy, yellow solid. Product was purified by silica column chromatography to afford **7** as yellow oil. Yield 69%. ¹H NMR (500 MHz, CDCl₃): δ ppm 7.29-7.40 (m, 8H), 7.23-7.29 (m, 2H), 3.92 (d, *J*= 10.0 Hz, 2H), 3.69 (d, *J*= 10.0 Hz, 2H), 2.28-2.35 (m, 2H), 2.14-2.26 (m, 4H), 1.76 (m, 2H), 1.21-1.33 (m, 2H), 1.03-1.14 (m, 2H), ¹³C NMR (126 MHz, CDCl₃): δ ppm 141.15, 128.40, 128.15, 126.84, 60.92, 50.92, 31.58, 25.18. ESIMS (*m/z*) 295 [M+H]⁺, 317 [M+Na]⁺, 293 [M-H]⁻

tert-butyl 2,2',2'',2'''-(2,2'-(1S,2S)-cyclohexane-1,2-diylbis(benzylazanediy))bis(ethane-2,1-diyl))bis(azanetriyl)tetraacetate (8)

[0161] To a solution of compound **7** (294 mg, 1.0 mmol) and compound S2 (739 mg, 2.1 mmol, 2.1 equiv) in DMF was added sodium carbonate (317 mg, 3 mmol, 3 equiv). The solution was heated for 24 h at 60°C under N₂. Sodium carbonate was removed by filtration. The filtrate was washed with H₂O and aqueous phase extracted twice with EtOAc. The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo. Product was purified by silica column chromatography to afford **8** as yellow oil. Yield 88%. ¹H NMR (500 MHz, CDCl₃): δ ppm 7.07-7.28 (m, 10H), 3.73 (d, *J*= 10.0 Hz, 2H), 3.37 (d, *J*= 10.0 Hz, 2H), 3.26 (s, 8H), 2.53-2.71 (m, 10H), 1.35-1.63 (m, 43H). ¹³C NMR (126 MHz, CDCl₃): δ ppm 170.54, 141.11, 128.84, 127.80, 126.36, 80.46, 61.02, 60.23, 55.96, 54.82, 53.86, 48.49, 28.08, 26.61, 26.04, 20.92, 14.17. ESIMS (*m/z*) 837 [M+H]⁺, 859 [M+Na]⁺, 835 [M-H]⁻

tert-butyl 2,2',2'',2'''-(2,2'-(1S,2S)-cyclohexane-1,2-diylbis(azanediyl))bis(ethane-2,1-diyl))bis(azanetriyl)tetraacetate (9)

[0162] To a solution of compound **8** (836 mg, 1.0 mmol) in methanol (7 mL) was added Pd/C (150 mg, 10 wt %). Hydrogen gas was bubbled through the solution for 3 min, and then the reaction mixture was stirred under hydrogen for 24 h. The Pd/C was filtered out over Celite, rinsing well with methanol, and the filtrate was evaporated to dryness in vacuo. The crude product was purified by silica gel column chromatography. Product fractions were combined and concentrated in vacuo to afford the product **8** as a waxy yellow solid. Yield 90%. ¹H NMR (500 MHz, MeOD): δ ppm 3.20-3.70 (m, 18H), 1.49-1.87 (m, 42H). ¹³C NMR (126 MHz, MeOD): δ ppm 172.15, 81.80, 56.71, 56.48, 51.54, 48.71, 44.20, 27.36, 25.43, 21.42. ESIMS (*m/z*) 657 [M+H]⁺, 679 [M+Na]⁺, 655 [M-H]⁻

tert-butyl 2,2'-(2-((1S,2S)-2-((2-(bis(2-tert-butoxy-2-oxoethyl)amino)ethyl)(2-tert-butoxy-2-oxoethyl)amino)cyclohexylamino)ethylazanediy)diacetate (10).


[0163] To a solution of compound 9 (328 mg, 0.5 mmol) and sodium carbonate (105.99 mg, 2 mmol, 2.0 equiv) in dry acetonitrile was added dropwise a solution of tertbutyl bromoacetate (74 μ L, 0.5 mmol, 1.0 equiv). The reaction mixture was stirred at 18 h at room temperature. Sodium carbonate was filtered and the filtrate concentrated in vacuo to dryness. EtOAc and water were added and aqueous layer were extracted twice with EtOAc. The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo to afford a waxy, yellow solid. Product was purified by silica column chromatography to afford **10** as yellow oil. Yield 85%. ¹H NMR (500 MHz, CDCl₃): δ ppm 3.30-3.40 (m, 20H), 1.10-1.45 (m, 42H). ¹³C NMR (126 MHz, CDCl₃): δ ppm 170.58, 170.48, 170.30, 170.14, 82.48, 80.92, 80.73, 80.33, 59.86, 56.55, 56.11, 55.85, 52.90, 50.54, 43.15, 41.60. ESIMS (m/z) 771 [M+H]⁺, 793 [M+Na]⁺, 769 [M-H]⁻

tert-butyl 2,2'-(2-(((1S,2S)-2-((2-(bis(2-tert-butoxy-2-oxoethyl)amino)ethyl)(2-(4-methyl-2-oxo-1,2-dihydroquinolin-7-ylamino)-2-oxoethyl)amino)cyclohexyl)(2-tert-butoxy-2-oxoethyl)amino)ethylazanediy)diacetate (11a).

[0164] Prepared in a similar way as compound 5a, except compound 10 was used instead of compound 4. Yield 52%. ¹H NMR (500 MHz, CDCl₃): δ ppm 7.52-7.64 (m, 3H), 6.38 (m, 1H), 2.15-3.44 (m, 25H), 1.23-1.43 (m, 53H). ESIMS (m/z) 985 [M+H]⁺, 1007 [M+Na]⁺, 983 [M-H]⁻

tert-butyl 2,2'-(2-(((1S,2S)-2-((2-(bis(2-tert-butoxy-2-oxoethyl)amino)ethyl)(2-tert-butoxy-2-oxoethyl)amino)cyclohexyl)(2-oxo-2-(2-oxo-4-(trifluoromethyl)-1,2-dihydroquinolin-7-ylamino)ethyl)amino)ethylazanediy)diacetate (11b).

[0165] Prepared in a similar way as compound 5b, except compound 10 was used instead of compound 4. Yield 52%. ¹H NMR (500 MHz, CDCl₃): δ ppm 7.44-7.62 (m, 3H), 6.87 (s, 1H), 2.50-3.50 (m, 22H), 1.33-1.44 (m, 53H). ESIMS (m/z) 985 [M+H]⁺, 1007 ESIMS (m/z) 1039 [M+H]⁺, 1061 [M+Na]⁺, 1037 [M-H]⁻



tert-butyl 2,2'-2-(((1S,2S)-2-((2-(bis(2-tert-butoxy-2-oxoethyl)amino)ethyl)(2-(4-methyl-2-oxo-1-(prop-2-ynyl)-1,2-dihydroquinolin-7-ylamino)-2-oxoethyl)amino)cyclohexyl)(2-tert-butoxy-2-oxoethyl)amino)ethylazanediyl)diacetate (13).

[0166] Prepared in a similar way as compound 11a, except compound S8 was used instead of compound S5. Yield 52%. ¹H NMR (500 MHz, CDCl₃): δ ppm 7.82-8.10 (m, 2H), 7.56 (m, 1H), 6.49 (s, 1H), 5.09 (s, 2H), 4.24 (s, 1H). ESIMS (m/z) 1023 [M+H]⁺, 1045 [M+Na]⁺, 1021 [M-H]⁻

di-tert-butyl 3,6,12-tris(2-tert-butoxy-2-oxoethyl)-9-(quinolin-2-ylmethyl)-3,6,9,12-tetraazatetradecane-1,14-dioate (15).

[0167] Prepared in a similar way as compound 5a, except compound S9 was used instead of compound 5a. Yield 75%. ¹H NMR (500 MHz, CDCl₃): δ ppm 8.10 (d, *J* = 5.0 Hz, 1H), 7.99 (d, *J* = 5.0 Hz, 1H), 7.75 (d, *J* = 5.0 Hz, 1H), 7.60-7.66 (m, 2H), 7.47 (t, *J* = 5.0 Hz, 1H), 3.95 (s, 2H), 3.46-3.51 (m, 2H), 3.39 (s, 4H), 3.32-3.35 (m, 4H), 2.72-2.86 (m, 12 H), 1.34-1.43 (m, 45H). ¹³C NMR (126 MHz, CDCl₃): δ ppm 171.02, 169.32, 166.73, 160.96, 147.90, 136.80, 129.69, 129.35, 127.96, 127.79, 126.44, 121.56, 81.97, 81.25, 61.99, 58.78, 56.98, 56.45, 53.24, 52.39, 52.00, 49.75, 47.56, 44.74, 28.52. ESIMS (*m/z*) 858 [M+H]⁺, 880 [M+Na]⁺, 856 [M-H]⁻

Compound 6a, 6b, 12a, 12b, 14, and 16.

[0168] To the corresponding ester was added deprotection mixture (TFA/CH₂Cl₂/iPr₃SiH, 5:5:1.8, v/v, 11.8 mL). After stirring for 24 h, toluene (10 mL) was added, and the solvent was removed by evaporation under reduced pressure. Ethyl acetate (5 mL) was added and the heterogeneous mixture was stirred for 1 h at 60 °C. The resulting precipitate was filtered off, washed with ethyl acetate (5 mL), and mixed with water (20 mL). Lyophilization afforded the pure compound.


Compound iii

[0169] A cyclohexyl analog of the metal chelator was prepared with methylenecarboxylate pendant groups and a sensitizing chromophore (carbostyryl 124) appended to one of the central nitrogens (**compound iii**). The synthesis of **compound iii** was remarkably efficient (8 steps, 45% overall yield). Moreover, it can be scaled up and altered to prepare different derivatives, as evidenced by the incorporation of a single chromophore into the structure. Given its position in the molecule, the amide oxygen between the cyclohexyl nitrogen and the chromophore may coordinate to a bound Tb ion. This coordination in turn would allow for efficient sensitization of metal luminescence and result in a high quantum yield of emission. Indeed this has proved to be the case. The quantum yield of **compound iii** exceeded 50% in water, making it among the most efficient luminescent Tb complexes known.

[0170] Reagents and conditions: (a) Boc₂O, DCM, 0°C — RT, 12 h, 92%. (b) PhCHO, MeOH, reflux, 10 h then NaBH₄ (2.1 equiv), 0°C — RT, 4 h, 95%. (c) BrCH₂CH₂Br, DMF, 60°C, 24 h, 80%. (d) TFA/DCM, RT, 24 h then t-butyl bromoacetate (4.0 equiv), Na₂CO₃ (4.0 equiv), MeCN, 24 h, 85%. (e) Pd/C (10 wt %), H₂, RT, 24 h, 90%. (f) t-butyl

bromoacetate (1.0 equiv), Na₂CO₃ (1.0 equiv), MeCN, 18 h, 85%. (g) cs-124-COCH₂Cl, Na₂CO₃, DMF, 60°C, 24 h, 60%. (h) TFA/CH₂Cl₂, RT, 24 h, 99%.

Synthesis of iii



[0171] The introduction of two rigid cyclohexyl groups into the otherwise flexible backbone provides a degree of pre-organization to the molecule that serves to increase thermodynamic and kinetic stability while preserving fast metallation kinetics. Polyaminocarboxylates with cyclohexane incorporated into the backbone are not unprecedented. CHX-A-DTPA has been extensively tested as a binder of ¹¹¹In, ^{86/90}Y and other radiometals since its introduction in the early 1990's, and analogs of triethylene tetraamine hexaacetic acid (TTHA) with a single ring structure have been described. A DTPA analog with two cyclohexane rings was also described as a Gd complexing agent.

Results and Discussion

[0172] All of the complexes prepared show characteristic lanthanide emission spectra. UV-Vis absorption spectra closely matched those of previously reported carbostyryl-sensitized

complexes. Measurement of luminescent lifetimes in H₂O and D₂O and fitting to the Horrocks and Sudnick equation²³ showed that water is excluded from the inner coordination sphere (Table 1). Most notably, exceptionally high quantum yields of 0.50 and 0.40 were observed in aqueous buffer for the Tb(III) and Eu(III) complexes of **12a** and **12b**, respectively, which are among the highest reported in the literature. The efficient emission and lack of bound waters support the hypothesis that inner substitution positions the sensitizer such that it remains coordinated to the metal center.

Table 1. Measurements of luminescent lifetimes in H₂O and in D₂O, number of water in inner coordination sphere, and quantum yield for select Tb(III) and Eu(III) complexes.

Compound	t _{H2O}	t _{D2O}	Number of Water	Quantum Yield
Tb-12a	1.81	1.83	0.03	0.50
Tb-6a	1.91	1.93	0.02	0.54
Eu-12b	1.08	1.54	0.29	0.40
Eu-6b	0.97	1.38	0.32	0.36

[0173] Practical use of lanthanide luminophores in solution phase bioassays or as imaging probes requires stable metal retention at high dilution in the presence of competing chelators or other metals. In general, cryptates or macrocycles are more kinetically inert than relatively flexible, linear chelators.⁴ However, they typically have slow metal association kinetics and require metallation at elevated temperatures, which complicates their use as antibody conjugates or with other heat-sensitive preparations (the Lumi4-Tb cryptate is a notable exception). Introduction of a pre-organized, cyclic moiety into an otherwise linear chelator can induce rigidity and yield more kinetically and/or thermodynamically stable complexes.²⁴ For example, incorporation of trans-1,2 diaminocyclohexane into the backbone of DTPA and TTHA improved the kinetic stability of radiometal complexes.²⁵⁻²⁶ Ge and Selvin reported enhanced kinetic stability of a 9-dentate polyaminocarboxylate chelate that incorporated 1-oxa-4,7-diazacyclononane.²⁰

[0174] The kinetic inertness of **Tb—12a** and **Eu—12b** was compared to the highly stable macrocycles Tb—DOTAm-Phen and Eu—DOTA-Phen and the linear complex, Tb – cs124-DTPA.^{6,27} Luminescence intensity was monitored after dilution to 5 nM in tris-buffered saline (TBS, pH 7.6) that contained the competitive additive EDTA (1 mM) (**FIG. 2**). After 48 h in EDTA solution, **Tb—12a** and the DOTA-based complexes retain their integrity, whereas the linear DTPA complex is completely dissociated from Tb(III) after only 10 h. The cyclic TTHA-based complexes **Tb—12a** and **Eu—12b** were still more than 40% in emissive after 48 h.

The EDTA challenge assay results show that incorporation of a cyclohexane ring into the TTHA backbone imparts considerable solution stability while preserving fast metallation kinetics.

[0175] In summary, we have demonstrated that cyTTHA is a versatile scaffold for preparing emissive lanthanide complexes. An efficient and flexible synthesis makes it possible to easily vary sensitizer moieties, and one may envision alteration of the number or type of chelating groups. Conjugation to biomolecules could be achieved by functionalizing the cyclohexane ring, as has been reported for similar diaminocyclohexane-derived chelators.²⁸⁻²⁹ The carbostyryl-sensitized complexes **Tb—12a** and **Eu—12b** have exceptional quantum yields of emission and excellent kinetic stability and are thus suitable for time-gated imaging and bioanalytical applications.

[0176] In order to show that high levels of kinetic inertness can be achieved with bis-diaminocycloalkyl chelators, **compound iii** and Tb were mixed together in buffer at a 1:1 ratio. Complete metallation, as judged by formation of green Tb luminescence, occurred in less than 15 min. The resulting complex was then diluted to a final concentration of 5 nM in buffer solution that contained a much higher concentration (1 mM) of a competing chelator, ethylene diamine tetraacetic acid (EDTA). By observing the metal luminescence over time, the kinetic inertness of **compound iii** relative to that of other known chelators was assessed.

[0177] FIG. 3 shows the remarkable kinetic stability of the **compound iii**-Tb analog. Like the well known stable chelator DOTA and its amide-functionalized derivative (DOTAm), **compound iii** equilibrates with the EDTA solution in 2-3 h and remains essentially stable for 2 days. By contrast, the flexible DTPA complex is completely dissociated after ca. 10 h. The **compound iii** scaffold may be synthetically modified to exhibit similar stability and kinetic inertness with many other functionally useful metal ions.

[0178] It should be emphasized that the above-described embodiments of the present disclosure are merely possible examples of implementations, and are set forth only for a clear understanding of the principles of the disclosure. Many variations and modifications may be made to the above-described embodiments of the disclosure without departing substantially from the spirit and principles of the disclosure. All such modifications and variations are intended to be included herein within the scope of this disclosure.

References


- (1) Bunzli, J. C. *Chem. Rev.* **2010**, *110*, 2729.
- (2) Heffern, M. C.; Matosziuk, L. M.; Meade, T. J. *Chem Rev* **2014**, *114*, 4496.

- (3) Geissler, D.; Stufler, S.; Lohmannsroben, H. G.; Hildebrandt, N. *J. Am. Chem. Soc.* **2013**, *135*, 1102.
- (4) Mathis, G.; Bazin, H. In *Lanthanide Luminescence*; Hänninen, P., Härmä, H., Eds.; Springer Berlin Heidelberg: 2011; Vol. 7, p 47.
- (5) Rajendran, M.; Yapici, E.; Miller, L. W. *Inorg Chem* **2014**, *53*, 1839.
- (6) Xu, J.; Corneillie, T. M.; Moore, E. G.; Law, G. L.; Butlin, N. G.; Raymond, K. N. *J. Am. Chem. Soc.* **2011**, *133*, 19900.
- (7) Butler, S. J.; Lamarque, L.; Pal, R.; Parker, D. *Chemical Science* **2014**, *5*, 1750.
- (8) Rajapakse, H. E.; Reddy, D. R.; Mohandessi, S.; Butlin, N. G.; Miller, L. W. *Angew. Chem. Int. Ed. Engl.* **2009**, *48*, 4990.
- (9) Rajapakse, H. E.; Gahlaut, N.; Mohandessi, S.; Yu, D.; Turner, J. R.; Miller, L. W. *Proc. Natl. Acad. Sci. U S A* **2010**, *107*, 13582.
- (10) Mohandessi, S.; Rajendran, M.; Magda, D.; Miller, L. W. *Chem. -- Eur. J.* **2012**, *18*, 10825.
- (11) Zou, X.; Rajendran, M.; Magda, D.; Miller, L. W. *Bioconjug Chem* **2015**, *26*, 460.
- (12) Prat, O.; Lopez, E.; Mathis, G. *Anal Biochem* **1991**, *195*, 283.
- (13) Li, M.; Selvin, P. R. *J. Am. Chem. Soc.* **1995**, *117*, 8132.
- (14) Xiao, M.; Selvin, P. R. *J. Am. Chem. Soc.* **2001**, *123*, 7067.
- (15) Chen, J.; Selvin, P. R. *Journal of Photochemistry and Photobiology A: Chemistry* **2000**, *135*, 27.
- (16) Reddy, D. R.; Pedro Rosa, L. E.; Miller, L. W. *Bioconjugate Chem.* **2011**, *22*, 1402.
- (17) Heyduk, E.; Heyduk, T. *Anal Biochem* **1997**, *248*, 216.
- (18) Li, M.; Selvin, P. R. *Bioconjugate Chem.* **1997**, *8*, 127.
- (19) Krasnoperov, L. N.; Marras, S. A.; Kozlov, M.; Wirpsza, L.; Mustaev, A. *Bioconjug Chem* **2010**, *21*, 319.
- (20) Ge, P.; Selvin, P. R. *Bioconjug Chem* **2008**, *19*, 1105.
- (21) Burdinski, D.; Lub, J.; Pikkemaat, J. A.; Moreno Jalon, D.; Martial, S.; Del Pozo Ochoa, C. *Dalton Trans* **2008**, 4138.
- (22) Burdinski, D.; Pikkemaat, J. A.; Lub, J.; de Peinder, P.; Nieto Garrido, L.; Weyhermuller, T. *Inorg Chem* **2009**, *48*, 6692.

- (23) Horrocks, W. D.; Sudnick, D. R. *Journal of the American Chemical Society* **1979**, *101*, 334.
- (24) De Sousa, A. S.; Croft, G. J. B.; Wagner, C. A.; Michael, J. P.; Hancock, R. D. *Inorganic Chemistry* **1991**, *30*, 3525.
- (25) Brechbiel, M. W.; Gansow, O. A.; Pippin, C. G.; Rogers, R. D.; Planalp, R. P. *Inorganic Chemistry* **1996**, *35*, 6343.
- (26) Ouadi, A.; Loussouarn, A.; Morandea, L.; Remaud, P.; Faivre-Chauvet, A.; Webb, J.; Gestin, J. F. *Eur J Med Chem* **2004**, *39*, 467.
- (27) Weitz, E. A.; Chang, J. Y.; Rosenfield, A. H.; Morrow, E. A.; Pierre, V. C. *Chemical Science* **2013**, *4*, 4052.
- (28) Gestin, J. F.; Benoist, E.; Loussouarn, A.; Mishra, A. K.; Faivre-Chauvet, A.; Chatal, J. F. *New J. Chem.* **1997**, *21*, 1021.
- (29) Loussouarn, A.; Duflos, M.; Benoist, E.; Chatal, J.-F.; Le Baut, G.; Gestin, J.-F. *Journal of the Chemical Society, Perkin Transactions 1* **1998**, 237.
- (30) Price, E. W.; Orvig, C., *Chem Soc Rev* **2014**, *43*, 260-90.
- (31) Heffern, M. C.; Matosziuk, L. M.; Meade, T. J., *Chem Rev* **2014**, *114*, 4496-539.
- (32) Pierre, V. C.; Allen, M. J.; Caravan, P., *J Biol Inorg Chem* **2014**, *19*, 127-31.
- (33) Bunzli, J. C., *Chem. Rev.* **2010**, *110*, 2729-2755.
- (34) Hildebrandt, N.; Wegner, K. D.; Algar, W. R., *Coordination Chemistry Reviews* **2014**, *273*, 125-138.
- (35) Rajendran, M.; Yapici, E.; Miller, L. W., *Inorg Chem* **2014**, *53*, 1839-53.
- (36) Gestin, J. F.; Benoist, E.; Loussouarn, A.; Mishra, A. K.; Faivre-Chauvet, A.; Chatal, J. F., *New Journal of Chemistry* **1997**, *21*, 1021-1026.
- (37) Loussouarn, A.; Duflos, M.; Benoist, E.; Chatal, J.-F.; Le Baut, G.; Gestin, J.-F., *Journal of the Chemical Society, Perkin Transactions 1* **1998**, 237-242.
- (38) Ouadi, A.; Loussouarn, A.; Morandea, L.; Remaud, P.; Faivre-Chauvet, A.; Webb, J.; Gestin, J. F., *Eur J Med Chem* **2004**, *39*, 467-72.
- (39) Sun, Y.; Martell, A. E.; Reibenspies, J. H.; Reichert, D. E.; Welch, M. J., *Inorg Chem* **2000**, *39*, 1480-6.

I claim:

1. A compound according to Formula I or Formula II:



where n_1 and n_4 are 2;

where n_2 and n_3 are 1;

where L^1 , L^2 , L^3 , L^5 , and L^6 are none;

where R^2 , R^3 , and R^4 are each $-\text{CH}_2\text{COOH}$;

where R^1 is selected from the group consisting of $-\text{CH}_2\text{COOH}$, H, $-\text{CH}_2\text{PO}(\text{OH})_2$, $-\text{CH}_2\text{CONH}_2$, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl;

where R^5 , R^7 , and R^8 are each H;


where R^6 is selected from the group consisting of H, substituted and unsubstituted alkyl, halogen, CN, CF_3 , acyl, $-\text{SO}_2\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{R}^{10}$, $-\text{OR}^9$, $-\text{SO}_2\text{R}^9$, $-\text{COOR}^9$, $-\text{SO}_2\text{OR}^9$, $-\text{OC}(\text{O})\text{R}^9$, $-\text{C}(\text{O})\text{NR}^9\text{R}^{10}$, $-\text{NR}^9\text{C}(\text{O})\text{R}^{10}$, $-\text{NR}^9\text{SO}_2\text{R}^{10}$, $-\text{NO}_2$, $-\text{C}(\text{O})\text{NHNH}_2$, $-\text{NCO}$, $-\text{NCS}$, $-\text{N}_3$, amino acid,

peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, and 5-cholesten-3 β -ol;

where R⁹ and R¹⁰ are each independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl and substituted and unsubstituted heterocyclyl, or R⁹ and R¹⁰, together with the atoms to which they are attached, form a 5- to 7 membered heterocyclyl or heteroaryl;

where X¹ and X² are each independently selected from the group consisting of -COOH, -PO(OH)₂, and a sensitizer so long as at least one of X¹ and X² is a sensitizer;

where each occurrence of the sensitizer is independently chosen from any one of the following formulas:



where A, B, and C are each independently selected from N and CH;

where R is independently selected at each occurrence from H and $-\text{OCH}_3$;

where R' is independently selected at each occurrence from $-\text{CH}_3$, $-\text{CF}_3$, and $-\text{CH}_2\text{COOH}$;

where R'' is independently selected at each occurrence from H and $-\text{CH}_2\text{COOH}$; and

where R''' is independently selected at each occurrence from H and $-\text{CH}_3$.

2. The compound according to claim 1, wherein the compound is according to Formula I;


wherein R¹ is $-\text{CH}_2\text{COOH}$; and

wherein R⁶ is H.

3. The compound according to claim 1, wherein the compound is according to Formula II; and

wherein R¹ is -CH₂COOH.

4. The compound according to any one of claims 1-3, wherein each occurrence of the sensitizer has a formula according to




where R', R'', and R''' are as defined above.

5. The compound according to any one of claims 1-4, wherein at least one of X¹ and X² is -COOH.


6. The compound according to any one of claims 1-4, wherein both X¹ and X² are a sensitizer.

7. The compound according to claim 1, wherein the compound is




where X is CH₃ or CF₃.

8. The compound according to claim 1, wherein the compound is




where X is CH₃ or CF₃.


9. The compound according to claim 1, wherein the compound is



10. The compound according to claim 1, wherein the compound is



11. The compound according to claim 1, wherein the compound is selected from the group consisting of



where L^x is independently selected at each occurrence from none, substituted and unsubstituted alkyl, substitute and unsubstituted heteroalkyl, substituted and unsubstituted heteroaryl, and substituted and unsubstituted heterocycloalkyl;

where R^x is independently selected at each occurrence from H, a halogen, substituted and unsubstituted alkyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted heteroaryl, substituted and unsubstituted heterocycloalkyl.

12. A luminescent complex formed between a compound according to any one of claims 1-11 and a metal ion.

13. The luminescent complex according to claim 12, where the metal ion is selected from the group consisting of Eu(III) and Tb(III).

14. The luminescent complex according to claim 12, wherein the metal ion is a lanthanide.

15. A method of detecting the presence of an analyte in a sample, the method comprising:
(a) contacting the sample with a composition comprising a luminescent complex according to any one of claims 12-14;

(b) exciting the complex; and

(c) detecting luminescence from the complex.

16. A method of detecting the presence of an analyte in a sample, the method comprising:
(a) contacting the sample and a composition comprising a luminescent complex according to any one of claims 12-14 and a luminescence modifying group;

(b) exciting the complex; and

(c) determining a luminescent property of the sample;

wherein energy is transferred between the luminescent complex and the luminescence modifying group when the complex is excited; and

wherein the presence of the analyte results in a change in the luminescent property.

17. The method according to claim 16, wherein the complex and the luminescence modifying group are part of the same molecule.

18. The method according to claim 16, wherein the complex and the luminescence modifying group are part of different molecules.

19. The method according to any one of claims 15-18, wherein the analyte binds to an antibody, wherein the antibody is covalently linked to a member selected from a luminescence modifying group and a luminescent complex according to any one of claims 12-14.



20. A method of making a compound according to any one of claims 1-11, the method comprising:

alkylating a compound according to Formula I-C or Formula II-C with a compound according to Formula IV to produce a first intermediate;



alkylating the first intermediate with a compound according to Formula V to produce a second intermediate; and

deprotecting the second intermediate to produce the compound according to Formula I or Formula II;

where Formula I-C and Formula II-C are



where Formula IV and Formula V are



where n1 and n4 are 2;

where n2 and n3 are 1;

where L¹, L², L³, L⁵, and L⁶ are none;

where R², R³, and R⁴ are each -CH₂COOH or a -CH₂COOH that has been protected with a carboxylic acid protecting group;

where R¹ is selected from the group consisting of -CH₂COOH, H, -CH₂PO(OH)₂, -CH₂CONH₂, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl groups, optionally that have been protected with one or more protecting groups;

where R⁵, R⁷, and R⁸ are each H;


where R^6 is selected from the group consisting of H, substituted and unsubstituted alkyl, halogen, CN, CF_3 , acyl, $-SO_2NR^9R^{10}$, $-NR^9R^{10}$, $-OR^9$, $-SO_2R^9$, $-COOR^9$, $-SO_2OR^9$, $-OC(O)R^9$, $-C(O)NR^9R^{10}$, $-NR^9C(O)R^{10}$, $-NR^9SO_2R^{10}$, $-NO_2$, $-C(O)NHNH_2$, $-NCO$, $-NCS$, $-N_3$, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, and 5-cholesten-3 β -ol, optionally that have been protected with one or more protecting groups;

where R^9 and R^{10} are each independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl and substituted and unsubstituted heterocyclyl, or R^9 and R^{10} , together with the atoms to which they are attached, form a 5- to 7 membered heterocyclyl or heteroaryl;

where Y^5 and Y^6 are each independently a halogen;

where X^1 and X^2 are each independently selected from the group consisting of $-COOH$, $-PO(OH)_2$, and a sensitizer so long as at least one of X^1 and X^2 is a sensitizer;

where each occurrence of the sensitizer is independently chosen from any one of the following formulas:



where A, B, and C are each independently selected from N and CH;

where R is independently selected at each occurrence from H and $-OCH_3$;


where R' is independently selected at each occurrence from $-CH_3$, $-CF_3$, and $-CH_2COOH$;

where R'' is independently selected at each occurrence from H and $-CH_2COOH$; and

where R''' is independently selected at each occurrence from H and $-CH_3$.


21. The method according to claim 20, wherein the first alkylating step, the second alkylating step, or both comprise protecting one or more of R¹, R², R³, and R⁴ with a protecting group.

22. The method according to claim 20 or claim 21, wherein R², R³, and R⁴ are each –CH₂COOtBu.
23. The method according to any one of claims 20-22, wherein R¹ is -CH₂COOtBu.
24. The method according to any one of claims 20-23, wherein the first alkylating step, the second alkylating step, or both alkylating steps are performed at about room temperature.
25. The method according to any one of claims 20-24, wherein one or both of Y⁵ and Y⁶ are Cl.
26. The method according to any one of claims 20-25, wherein the method further comprises;
- alkylating a compound according to Formula I-B or Formula II-B with one or both of a compound according to Formula VI and a compound according to Formula VII followed by benzyl deprotection via hydrogenation to produce the compound according to Formula I-C or Formula II-C




I-B

II-B



VI




VII

where Y⁷ and Y⁸ are each independently a halogen.

27. The method according to claim 26, wherein one or both of Y⁷ and Y⁸ are Br.

28. The method according to claim 26 or claim 27, wherein the step of alkylating the compound according to Formula I-B or Formula II-B is performed at a temperature of about 60°C.

29. A compound according to Formula I or Formula II:



wherein,

n1 and n4 are independently selected from integers of from 1 to 5,

n2 and n3 are independently selected from integers of from 0 to 5;

R¹, R², R³ and R⁴ are independently selected from

H, -CH₂COOH, -CH₂PO(OH)₂, -CH₂CONH₂, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl;


R⁵, R⁶, R⁷ and R⁸, are independently selected from H, substituted and unsubstituted alkyl, halogen, CN, CF₃, acyl, -SO₂NR⁹R¹⁰, -NR⁹R¹⁰, -OR⁹, -SO₂R⁹, -COOR⁹, -SO₂OR⁹, -

OC(O)R⁹, -C(O)NR⁹R¹⁰ -NR⁹C(O)R¹⁰, -NR⁹SO₂R¹⁰, -NO₂, -C(O)NHNH₂, -NCO, -NCS, -N₃, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, 5-cholesten-3 β -ol, or R⁵, together with the atom to which it is attached and one or more of R⁶, R⁷, R⁸ forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl or substituted and unsubstituted heteroaryl;

R⁹ and R¹⁰ are independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl and substituted and unsubstituted heterocyclyl, or R⁹ and R¹⁰, together with the atoms to which they are attached, form a 5- to 7 membered heterocyclyl or heteroaryl;

L¹, L², L³, L⁴, L⁵, and L⁶, are independently absent or selected from substituted and unsubstituted alkyl;

X¹ and X² are independently selected from H, halogen, -CHO, -COOH, -PO(OH)₂, -CONH₂, -C(O)NHNH₂, -NCO, -NCS, -N₃, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, 5-cholesten-3 β -ol, substituted and unsubstituted alkyl, substituted and unsubstituted alkynyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, fluorophores or chromophores that absorb light of a wavelength in the range of about 300 to about 420 nm and a group of formula III:




III

wherein Y^1 , Y^2 , Y^3 , Y^4 are independently selected from H, substituted and unsubstituted alkyl, halogen, CN, CF_3 , acyl, $-SO_2NR^{11}R^{12}$, $-NR^{11}R^{12}$, $-OR^{11}$, $-SO_2R^{11}$, $-COOR^{11}$, $-SO_2OR^{11}$, $-OC(O)R^{11}$, $-C(O)NR^{11}R^{12}$, $-NR^{11}C(O)R^{12}$, $-NR^{11}SO_2R^{12}$, and $-NO_2$, or Y^1 together with the atom to which it is attached and one or more of Y^2 , Y^3 , Y^4 and forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl or substituted and unsubstituted heteroaryl;


R^{11} and R^{12} are independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl and substituted and unsubstituted heterocyclyl, or R^{11} and R^{12} , together with the atoms to which they are attached, are optionally joined to form a 5- to 7 membered heterocyclyl or heteroaryl;

provided at least one of R^1 , R^2 , R^3 , R^4 , X^1 and X^2 are other than $-CH_2COOH$ or $-CH_2PO(OH)_2$ and further provided that the compound of Formula I or Formula II is not:



82

or



where R is CH₃ or CF₃.

30. The compound according to claim 29, wherein one or both of X¹ and X² are independently selected from halogen, -CONH₂, -CHO, -C(O)NHNH₂, -COOH, maleimidyl, thiazolidyl, haloacetyl, pyridyl disulfide, substituted and unsubstituted NHS ester, sulfonated NHS ester, succinimidyl, -NCO, -NCS, -N₃, substituted and unsubstituted alkynyl, tetrazolyl, substituted and unsubstituted cyclooctynyl, an amino acid moiety, and a phosphoramidite moiety.

31. The compound according to claim 29, wherein one or both of X¹ and X² are independently selected from tyramine, a tyramine derivative, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, and benzyl cytosine.


32. The compound according to claim 29, wherein one or both of X¹ and X² are independently selected from 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, and 5-cholesten-3β-ol.

33. The compound according to any one of claims 29-32, wherein R⁵, R⁶, R⁷, and R⁸ are independently selected from halogen, -CONH₂, -CHO, -C(O)NHNH₂, -COOH, maleimidyl, thiazolidyl, haloacetyl, pyridyl disulfide, substituted and unsubstituted NHS ester, sulfonated NHS ester, succinimidyl, -NCO, -NCS, -N₃, substituted and unsubstituted alkynyl, tetrazolyl, substituted and unsubstituted cyclooctynyl, an amino acid moiety, and a phosphoramidite moiety.

34. The compound according to any one of claims 29-32, wherein R⁵, R⁶, R⁷, and R⁸ are independently selected from tyramine, a tyramine derivative, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, and benzyl cytosine.

35. The compound according to any one of claims 29-32, wherein R⁵, R⁶, R⁷, and R⁸ are independently selected from 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, and 5-cholesten-3 β -ol.

36. The compound according to any one of claims 29-35, wherein the fluorophores or chromophores that absorb light of a wavelength in the range of about 300 to about 420 nm are selected from




where A and C are independently selected from N and CH; R is independently selected at each occurrence from H and $-\text{OCH}_3$; R' is selected from $-\text{CH}_3$, $-\text{CF}_3$, and $-\text{CH}_2\text{COOH}$; R'' is selected from H and $-\text{CH}_2\text{COOH}$; and R''' is selected from H and $-\text{CH}_3$.

37. The compound according to any one of claims 29-32, wherein L^3 , L^4 , L^5 , and L^6 are absent and R^5 , R^6 , R^7 , and R^8 are H.

38. The compound according to claim 37, wherein R^1 , R^2 , R^3 , and R^4 are $-\text{CH}_2\text{COOH}$.


39. The compound according to any one of claims 29-38, wherein one of X^1 and X^2 is –COOH and the other is a fluorophore or chromophore that absorbs light of a wavelength in the range of about 300 to about 420 nm.

40. The compound according to claim 38, wherein the fluorophore or chromophore is selected from



wherein A and C are independently selected from N and CH; R is independently selected at each occurrence from H and –OCH₃; R' is selected from –CH₃, –CF₃, and –CH₂COOH; R'' is selected from H and –CH₂COOH; R''' is selected from H and –CH₃ and R'''' is selected from H and –CH₂CCH.

41. The compound according to claim 39, wherein the fluorophore or chromophore is according to the formula



42. A luminescent complex formed between a compound according to any one of claims 29-41 and a metal ion.

43. The luminescent complex according to claim 42, where the metal ion is selected from the group consisting of Eu(III) and Tb(III).

44. The luminescent complex according to claim 42, wherein the metal ion is a lanthanide.

45. A method of detecting the presence of an analyte in a sample, the method comprising:
 (a) contacting the sample with a composition comprising a luminescent complex according to any one of claims 42-44;

(b) exciting the complex; and

(c) detecting luminescence from the complex.

46. A method of detecting the presence of an analyte in a sample, the method comprising:
 (a) contacting the sample and a composition comprising a luminescent complex according to any one of claims 42-44 and a luminescence modifying group;

(b) exciting the complex; and

(c) determining a luminescent property of the sample;

wherein energy is transferred between the luminescent complex and the luminescence modifying group when the complex is excited; and

wherein the presence of the analyte results in a change in the luminescent property.

47. The method according to claim 46, wherein the complex and the luminescence modifying group are part of the same molecule.

48. The method according to claim 46, wherein the complex and the luminescence modifying group are part of different molecules.

49. The method according to any one of claims 45-48, wherein the analyte binds to an antibody, wherein the antibody is covalently linked to a member selected from a luminescence modifying group and a luminescent complex according to any one of claims 42-44.



50. A method of making a compound according to any one of claims 29-41, the method comprising:

alkylating a compound according to Formula I-C or Formula II-C with a compound according to Formula IV to produce a first intermediate;



alkylating the first intermediate with a compound according to Formula V to produce a second intermediate; and

deprotecting the second intermediate to produce the compound according to Formula I or Formula II;

where Formula I-C and Formula II-C are



where Formula IV and Formula V are



wherein,

n1 and n4 are independently selected from integers of from 1 to 5;

n2 and n3 are independently selected from integers of from 0 to 5;

L¹, L², L³, L⁴, L⁵ and L⁶, are independently absent or selected from substituted and unsubstituted alkyl;


R¹, R², R³ and R⁴ are independently selected from H, -CH₂COOH, -CH₂PO(OH)₂, -CH₂CONH₂, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl, optionally that have been protected with one or more protecting groups;

R⁵, R⁶, R⁷ and R⁸, are independently selected from H, substituted and unsubstituted alkyl, halogen, CN, CF₃, acyl, -SO₂NR⁹R¹⁰, -NR⁹R¹⁰, -OR⁹, -SO₂R⁹, -COOR⁹, -SO₂OR⁹, -OC(O)R⁹, -C(O)NR⁹R¹⁰ -NR⁹C(O)R¹⁰, -NR⁹SO₂R¹⁰, -NO₂, -C(O)NHNH₂, -NCO, -NCS, -N₃, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, 5-cholesten-3β-ol, or R⁵, together with the atom to which it is attached and one or more of R⁶, R⁷, R⁸ forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl or substituted and unsubstituted heteroaryl, optionally that have been protected with one or more protecting groups;

where R⁹ and R¹⁰ are each independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl and substituted and unsubstituted heterocyclyl, or R⁹ and R¹⁰, together with the atoms to which they are attached, form a 5- to 7 membered heterocyclyl or heteroaryl;

where Y⁵ and Y⁶ are each independently a halogen;

X¹ and X² are independently selected from H, halogen, -CHO, -COOH, -PO(OH)₂, -CONH₂, -C(O)NHNH₂, -NCO, -NCS, -N₃, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, 5-cholesten-3β-ol, substituted and unsubstituted alkyl, substituted and unsubstituted alkynyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, fluorophores or chromophores that absorb light of a wavelength in the range of about 300 to about 420 nm and a group of formula III:



III

wherein Y^1 , Y^2 , Y^3 , Y^4 are independently selected from H, substituted and unsubstituted alkyl, halogen, CN, CF_3 , acyl, $-SO_2NR^{11}R^{12}$, $-NR^{11}R^{12}$, $-OR^{11}$, $-SO_2R^{11}$, $-COOR^{11}$, $-SO_2OR^{11}$, $-OC(O)R^{11}$, $-C(O)NR^{11}R^{12}$, $-NR^{11}C(O)R^{12}$, $-NR^{11}SO_2R^{12}$, and $-NO_2$, or Y^1 together with the atom to which it is attached and one or more of Y^2 , Y^3 , Y^4 and forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl or substituted and unsubstituted heteroaryl;

R^{11} and R^{12} are independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl and substituted and unsubstituted heterocyclyl, or R^{11} and R^{12} , together with the atoms to which they are attached, are optionally joined to form a 5- to 7 membered heterocyclyl or heteroaryl;

provided at least one of R^1 , R^2 , R^3 , R^4 , X^1 and X^2 are other than $-CH_2COOH$ or $-CH_2PO(OH)_2$

51. The method according to claim 50, wherein the first alkylating step, the second alkylating step, or both comprise protecting one or more of R^1 , R^2 , R^3 , and R^4 with a protecting group.


52. The method according to claim 50 or claim 51, wherein R^1 , R^2 , R^3 , and R^4 are each $-CH_2COOtBu$.

53. The method according to any one of claims 50-52, wherein the first alkylating step, the second alkylating step, or both alkylating steps are performed at about room temperature.


54. The method according to any one of claims 50-53, wherein one or both of Y^5 and Y^6 are Cl.

55. The method according to any one of claims 50-54, wherein the method further comprises;


alkylating a compound according to Formula I-B or Formula II-B with one or both of a compound according to Formula VI and a compound according to Formula VII followed by benzyl deprotection via hydrogenation to produce the compound according to Formula I-C or Formula II-C




I-B



II-B




VI



VII

where Y^7 and Y^8 are each independently a halogen.

56. The method according to claim 55, wherein one or both of Y^7 and Y^8 are Br.
57. The method according to claim 55 or claim 56, wherein the step of alkylating the compound according to Formula I-B or Formula II-B is performed at a temperature of about 60°C .
58. A compound of Formula VIII:



I

wherein,

A^1 and A^2 form together with the atoms to which they are attached a C_3 - C_8 -cycloalkyl group;

A³ and A⁴ form together with the atoms to which they are attached a C₃-C₈-cycloalkyl group;


n₅, n₆, n₇, n₈, n₉ and n₁₀ are independently selected from integers of from 0 to 5 inclusive;

n₁₁ is independently selected from integers of from 1 to 10 inclusive;

n₁₂ and n₁₃ are independently selected from integers of from 1 to 16 inclusive;

i is independently selected from integers of from 1 to n₁₂ inclusive;

j is independently selected from integers of from 1 to n₁₃ inclusive;




nQⁱ and S^j are independently R, Rⁱ or R^j, where R, Rⁱ and R^j are independently selected from substituted and unsubstituted alkyl, halogen, CN, CF₃, acyl, -SO₂NR'R'', -NR'R'', -OR', -SO₂R', -COOR', -SO₂OR', -OC(O)R', -C(O)NR'R''-NR'C(O)R'', -NR'SO₂R'', -NO₂, -C(O)NHNH₂, -NCO, -NCS, -N₃, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, 5-cholesten-3β-ol or Rⁱ, together with the atom to which it is attached and one or more additional Rⁱ, forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl or substituted and unsubstituted heteroaryl, or R^j, together with the atom to which it is attached and one or more additional R^j forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl or substituted and unsubstituted heteroaryl;

R' and R'' are independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl and substituted and unsubstituted heterocyclyl;

L⁷, L⁸, L⁹, L¹⁰, L¹¹, and L¹² are independently absent, H or selected from substituted and unsubstituted heteroalkyl and substituted and unsubstituted alkyl;

X^3 , X^4 , X^5 , X^6 , X^7 and X^8 are independently selected from H, halogen, -CHO, -COOH, -PO(OH)₂, -CONH₂, -C(O)NHNH₂, -NCO, -NCS, -N₃, amino acid, peptidyl, phosphoramidite, substituted and unsubstituted NHS ester, sulfonated NHS ester, haloacetyl, tyramine, biotin, estrogen, trimethoprim, methotrexate, benzyl guanine, benzyl cytosine, 1,2-dialkyl-*sn*-glycero-3-phosphoethanolamine, 1,2-dialkyl-*sn*-glycero-3-phospho-L-serine, 1,1',2,2'-tetraoleoyl cardiolipin, D-erythro-sphingosine, sphingosine-1-phosphocholine, 5-cholesten-3 β -ol, substituted and unsubstituted alkyl, substituted and unsubstituted alkynyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, fluorophores or chromophores that absorb light of a wavelength in the range of about 300 to about 420 nm, and compounds according to formula IX:



IX


wherein Y^9 , Y^{10} , Y^{11} , Y^{12} are independently selected from H, substituted and unsubstituted alkyl, halogen, CN, CF₃, acyl, -SO₂NR^{13'}R^{13''}, -NR^{13'}R^{13''}, -OR^{13'}, -SO₂R^{13'}, -COOR^{13'}, -SO₂OR^{13'}, -OC(O)R^{13'}, -C(O)NR^{13'}R^{13''}, -NR^{13'}C(O)R^{13''}, -NR^{13'}SO₂R^{13''}, and -NO₂, or Y^9 together with the atom to which it is attached and one or more of Y^{10} , Y^{11} , Y^{12} and forms a substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclyl, substituted and unsubstituted aryl or substituted and unsubstituted heteroaryl;

$R^{13'}$ and $R^{13''}$ are independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl and substituted and unsubstituted heterocyclyl;

Z is selected from the group consisting of of -CH₂-, -CH₂CH₂-, -CH₂CH₂OCH₂CH₂-, and -CH₂CH₂SCH₂CH₂-.

59. The compound according to claim 58; wherein at least one of X^3 , X^4 , X^5 , X^6 , X^7 and X^8 is the fluorophore or chromophore that absorbs light of a wavelength in the range of about 300 to about 420 nm, and

wherein the fluorophore or chromophore is selected from the group consisting of



wherein A and C are independently selected from N and CH;


wherein R^{14} is independently selected at each occurrence from H and $-OCH_3$;

wherein $R^{14'}$ is selected from $-CH_3$, $-CF_3$, and $-CH_2COOH$;

wherein $R^{14''}$ is selected from H and $-CH_2COOH$; and

wherein $R^{14'''}$ is selected from H and $-CH_3$.


60. The compound according to claim 59, wherein the fluorophore or chromophore is a compound of formula:



wherein R^{14'}, R^{14''}, and R^{14'''} are as in Claim 7; and

wherein R^{14''''} is selected from H and -CH₃.


61. The compound according to claim 58, wherein the compound is selected from the group consisting of



where L_Y is independently at each occurrence selected from the group consisting of none, substituted and unsubstituted alkyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted heteroaryl, and substituted and unsubstituted heterocycloalkyl;

where R_Y is independently at each occurrence selected from the group consisting of hydrogen, a halogen, substituted and unsubstituted alkyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted heteroaryl, and substituted and unsubstituted heterocycloalkyl.

62. The compound according to claim 61, wherein R_Y is selected from the group consisting of



63. A luminescent complex formed between a compound according to any one of claims 58-62 and a metal ion.


64. The luminescent complex according to claim 63, where the metal ion is selected from the group consisting of Eu(III) and Tb(III).

65. The luminescent complex according to claim 63, wherein the metal ion is a lanthanide.


66. The luminescent complex according to claim 63, wherein the metal ion is a stable or a radioactive isotope of a metal selected from the group consisting of Ga, In, Tl, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Sc, Y, Ti, Zr, Cr, Mn, Tc, Re, Fe, Ru, Co, Rh, Ir, Ni, Pd, Pt, Cu, Zn, Cd, Hg, Al, Ge, Sn, Pb, Sb, Bi, Te, Po, Mg, Ca, Sr, Ba, Ra, Ac, Th and U.

67. The compound according to claim 63, wherein the metal ion is selected from the group consisting of ⁶⁶Ga, ⁶⁷Ga, ⁶⁸, ¹¹¹In, ²⁰¹Tl, ¹⁴²Pr, ¹⁴⁹Pm, ¹⁵³Sm, ¹⁵³Gd, ¹⁵⁹Gd, ¹⁶⁶Ho, ¹⁷⁵Yb, ¹⁷⁷Lu, ⁴⁷Sc, ⁹⁰Y, ⁸⁹Zr, ⁵¹Cr, ^{99m}Tc, ¹⁸⁸Re, ¹⁸⁶Re, ⁵⁷Co, ^{101m}Rh, ⁶²Cu, ⁶⁴Cu, ⁶⁷Cu, ^{117m}Sn, ²⁰³Pb, ²¹²Pb, ²¹²Bi, ²¹³Bi, ²²³Ra, and ²²⁵Ac.


68. A method of detecting the presence of an analyte in a sample, the method comprising:
- (a) contacting the sample with a composition comprising a luminescent complex according to any one of claims 63-67;
 - (b) exciting the complex; and
 - (c) detecting luminescence from the complex.
69. A method of detecting the presence of an analyte in a sample, the method comprising:
- (a) contacting the sample and a composition comprising a luminescent complex according to any one of claims 63-67 and a luminescence modifying group;
 - (b) exciting the complex; and
 - (c) determining a luminescent property of the sample;
- wherein energy is transferred between the luminescent complex and the luminescence modifying group when the complex is excited; and
- wherein the presence of the analyte results in a change in the luminescent property.
70. The method according to claim 69, wherein the complex and the luminescence modifying group are part of the same molecule.
71. The method according to claim 69, wherein the complex and the luminescence modifying group are part of different molecules.
72. The method according to any one of claims 69-71, wherein the analyte binds to an antibody, wherein the antibody is covalently linked to a member selected from a luminescence modifying group and a luminescent complex according to any one of claims 63-67.




DOTA




NOTA



DTPA



Lumi4



CHX-A''-DTPA

FIG. 1




FIG. 2




FIG. 3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 17/50245

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: 5-6, 12-28, 36, 39, 41-57, 68-72
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
(continued on supplemental page)

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-2, 29-30 and (37-38, 40)/(29-30)

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 17/50245

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(8) - A61K 51/04, A61K 49/00, A61K 49/08 (2017.01)
 CPC - C09B 23/086, C09B 23/0066, A61K 49/085

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History Document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History Document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History Document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,434,287 A (Gansow et al.) 18 July 1995 (18.07.1995); Figure 1	1-2, 29-30, (37-38, 40)/(29-30)
A	US 2016/194690 A1 (Rutgers, The State University of New Jersey) 07 July 2016 (07.07.2016); para [0091]	1-2, 29-30, (37-38, 40)/(29-30)
A	US 2010/0204467 A1 (Lamarque et al.) 12 August 2010 (12.08.2010); para [0069]	1-2, 29-30, (37-38, 40)/(29-30)

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

12 December 2017

Date of mailing of the international search report

27 DEC 2017

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
 P.O. Box 1450, Alexandria, Virginia 22313-1450
 Facsimile No. 571-273-8300

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
 PCT OSP: 571-272-7774

--continued from Box No. III--

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Group I+: Claims 1-4, 7-11, 29-35, 37-38, 40, 58-67, directed to a compound of claim 1, of formula I or II(VIII). The compound of claim 1 will be searched to the extent that it encompasses the first species of claim 1, represented by the compound of formula I where n1 and n4 are 2; where n2 and n3 are 1; where L1, L2, L3, L5, and L6 are none; where R2, R3, and R4 are each -CH₂COOH; R1 is CH₂COOH; R5, R7 and R8 are H; R6 is H; R9 and R10 are H; X1 is COOH; and X2 is a sensitizer, which is the first structure listed. It is believed that claims 1-2, 29-30 and (37-38, 40)/(29-30), read on this first named invention, and thus these claims will be searched without fee. Applicant is invited to elect additional compounds of claim 1, wherein each additional compound elected will require one additional invention fee. Applicants must specify the claims that encompass any additionally elected compound. Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the '+' group(s) will result in only the first claimed invention to be searched. Additionally, an exemplary election wherein different actual variables are selected is suggested. An exemplary election would be a compound of claim 1, represented by the first formula of claim 1, formula I where n1 and n4 are 2; where n2 and n3 are 1; where L1, L2, L3, L5, and L6 are none; where R2, R3, and R4 are each -CH₂COOH; R1 is CH₂COOH; R5, R7 and R8 are H; R6 is sphingosine-1-phosphocholine; R9 and R10 are H; X1 is COOH; and X2 is a sensitizer, which is the first structure listed (i.e., claims 1 and 29-30).

The group of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features:

Group I+ includes the technical feature of a unique compound of claim I of formula I or II(VIII), which is not required by any other invention of Group I+.

Common technical features:

The inventions of Group I+ share the technical feature of a compound of claim I of formula I or II(VIII).

These shared technical features, however, do not provide a contribution over the prior art, as being obvious over US 2016/194690 A1 to Rutgers, The State University of New Jersey (hereinafter Rutgers). Rutgers discloses a compound of formula II wherein n4 is 2; where n2 and n3 are 1; where L1, L2 are none; where R3 and R4 are each -CH₂COOH; X2 is COOH; and X1 is a sensitizer, which is the 6th structure listed wherein R' is CH₃; R'' is H; R''' is H (Fig. 4, compound DTPA-cs124), but does not disclose an additional amine comprising R1 and R2 bound to the end of the polyamine chain. However, Rutgers further discloses additional compounds comprising an additional amine linker segment, wherein n1 is 2 (para [0202]: Table 2, compound A). It would have been obvious to one with skill in the art to prepare derivatives of the compound disclosed comprising an additional amine containing CH₂COOH moieties (as utilized on one end of the amine chain) in order to provide for additional sites of chelation. It would have been obvious to one with skill in the art to link the sensitizer moiety (quinoline amide) to any of the amine sites of the tetraamine chain through routine experimentation preparing similar compounds which are metal chelators comprising a sensitizer moiety.

As said compound and compositions were known in the art at the time of the invention, these cannot be considered special technical features that would otherwise unify the inventions of Groups I+. The inventions of Group I+ thus lack unity under PCT Rule 13.

Note: Claims 5-6, 12-28, 36, 39, 41-57, 68-72 have been found to be unsearchable because they are not drafted in accordance with the second and third sentences of Rule 6.4(a).